Wheatgrass molecules Formulation Repprt (1).docx

Check the text below is correct, then click Analyse. You can edit it first if the automatic extraction missed something.

Document text

Identify herbal or nutraceutical formulations publicly reported for Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid targeting Oral Cancer, along with dosage forms and bioactive components.Search PubMed, AYUSH, and patent databases for formulations containing Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid related to Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling. Extract composition, ratios, and dosage.List polyherbal or proprietary blends mentioning Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid with claimed therapeutic effect on Oral Cancer. Include dosage form and indication.Retrieve formulations from pharmacopoeias or AYUSH monographs combining Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling in Oral Cancer.Identify commercial supplements using Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid marketed for Oral Cancer, summarizing their ingredients and delivery systems.
There are individual experimental and commercial formulations using apigenin, quercetin/rutin, flavonoid‑rich extracts and chlorophyll/chlorophyllin for oral or general cancer support, but publicly reported polyherbal formulations that combine all of chlorophyll(‑in), apigenin/flavonoids, quercetin/rutin and abscisic acid specifically for oral cancer are essentially absent; existing data are mostly single‑molecule or partial combinations, and often preclinical rather than approved AYUSH or pharmacopoeial products. HYPERLINK \l "fn1" \h [1] HYPERLINK \l "fn2" \h [2] HYPERLINK \l "fn3" \h [3] HYPERLINK \l "fn4" \h [4] HYPERLINK \l "fn5" \h [5] HYPERLINK \l "fn6" \h [6] HYPERLINK \l "fn7" \h [7]
Below I’ve organized what is actually available into: (1) preclinical formulations and models related to oral cancer, (2) mechanistic roles of the four bioactives in oral cancer biology, and (3) commercial or nutraceutical products that partially match your matrix.

Scope and evidence limitations
PubMed and recent oncology/nutraceutical reviews show strong preclinical evidence for apigenin and quercetin in oral squamous cell carcinoma (OSCC), including nano‑formulations and oral administration, but these are usually single‑compound or simple combinations, not complex polyherbal blends with all the specified actives. HYPERLINK \l "fn8" \h [8] HYPERLINK \l "fn4" \h [4] HYPERLINK \l "fn6" \h [6] HYPERLINK \l "fn7" \h [7] HYPERLINK \l "fn1" \h [1]
AYUSH monographs and pharmacopoeias list numerous antioxidant and “blood purifier” formulations, but explicit indications for “oral cancer” with defined ratios including chlorophyll(‑in), apigenin, quercetin/rutin and abscisic acid together are not reported in accessible public documents. HYPERLINK \l "fn9" \h [9]
Patent‑style and research‑strategy content in your attached file describes sulforaphane–resveratrol–genistein oral strips for oral cancer, which is conceptually similar but uses different lead phytochemicals and does not include chlorophyll, quercetin or abscisic acid. HYPERLINK \l "fn10" \h [10]
Given this, I’ll focus on formulations and systems where at least one of your target molecules is specified, especially when oral cavity or OSCC is the target.

Apigenin formulations relevant to oral cancer
Oral apigenin in preclinical cancer models
Reviews describe oral apigenin (20–50 µg per mouse, 20 weeks) reducing tumor volume and eliminating distant organ metastasis in carcinogen‑induced models; while not always OSCC, the mechanisms (apoptosis, cell‑cycle arrest, NF‑κB and PI3K/Akt modulation) are directly relevant to oral cancer biology. HYPERLINK \l "fn11" \h [11] HYPERLINK \l "fn6" \h [6] HYPERLINK \l "fn8" \h [8]
Mechanistically, apigenin induces G2/M or G0/G1 cell‑cycle arrest, promotes intrinsic apoptosis (Bax/Bcl‑2, caspases), and inhibits pro‑inflammatory pathways (NF‑κB, COX‑2), which aligns with your focus on antioxidant, cell‑cycle arrest, pro‑inflammatory and signaling modulation endpoints. HYPERLINK \l "fn6" \h [6] HYPERLINK \l "fn7" \h [7] HYPERLINK \l "fn1" \h [1] HYPERLINK \l "fn8" \h [8]
Delivery systems and dosage forms
Apigenin is investigated in nano‑formulations (polymeric nanoparticles, liposomes) aimed at improving oral bioavailability and targeted delivery; dosage forms discussed include oral capsules, suspensions and experimental oral films/strips, but cancer type‑specific dosing ranges are not standardized and usually reported as mg/kg in animals. HYPERLINK \l "fn7" \h [7] HYPERLINK \l "fn1" \h [1] HYPERLINK \l "fn8" \h [8] HYPERLINK \l "fn6" \h [6]
Some combination strategies pair apigenin with other flavonoids such as quercetin or luteolin in systemic cancers, but detailed compositions (exact mg ratios and excipient matrices) are rarely fully disclosed outside patents and are not OSCC‑focused in the publicly accessible literature. HYPERLINK \l "fn12" \h [12] HYPERLINK \l "fn13" \h [13] HYPERLINK \l "fn7" \h [7]

Quercetin and rutin in oral cancer
Defatted seed extracts (Neem and bitter gourd)
A recent study on defatted seeds of Azadirachta indica (neem) and Momordica charantia (bitter gourd) identified quercetin and rutin, along with tannic acid, as main flavonoids. HYPERLINK \l "fn2" \h [2]
Ethanolic extracts showed strong antioxidant activity in DPPH and reducing power assays, and aqueous extracts exhibited maximum antiproliferative activity against KB mouth carcinoma cell lines in MTT assays, supporting relevance to oral cancer. HYPERLINK \l "fn2" \h [2]
While the work clearly implicates quercetin and rutin in antiproliferative and antioxidant effects, the formulation is described as seed extracts rather than a defined nutraceutical product, and exact quantitative composition (mg of quercetin/rutin per dose) is not reported. HYPERLINK \l "fn2" \h [2]
Quercetin as therapeutic agent in oral cancer
A 2025 systematic review highlights quercetin as a promising therapy for oral squamous cell carcinoma, noting effects on apoptosis, metastasis suppression, cell‑cycle arrest and chemosensitization. HYPERLINK \l "fn3" \h [3] HYPERLINK \l "fn4" \h [4]
Nano‑delivery systems (liposomes, polymeric nanoparticles, nanoemulsions) are emphasized for oral cancer to overcome poor systemic absorption; these are largely experimental but describe quercetin loading in the range of low‑mg/kg in animal models or tens to hundreds of mg/day in conceptual human supplements. HYPERLINK \l "fn4" \h [4] HYPERLINK \l "fn3" \h [3]
Mechanisms include modulation of PI3K/Akt, NF‑κB, MAPK and p53, supporting antioxidant, anti‑inflammatory, cell‑cycle arrest and cell‑signaling modulation roles directly in OSCC models. HYPERLINK \l "fn3" \h [3] HYPERLINK \l "fn12" \h [12] HYPERLINK \l "fn4" \h [4] HYPERLINK \l "fn7" \h [7]
Implicit composition and ratios
Typical quercetin nutraceuticals provide 500–1000 mg/day in capsules or tablets for antioxidant and general anti‑inflammatory claims, often combined with bromelain or vitamin C; flavonoid synergy is proposed but not oral‑cancer‑specific. HYPERLINK \l "fn13" \h [13] HYPERLINK \l "fn12" \h [12] HYPERLINK \l "fn7" \h [7]
Rutin appears as a co‑flavonoid at lower doses (e.g., 50–250 mg/day) in venotonic and antioxidant supplements; again, oral cancer indications are absent in mainstream commercial labels. HYPERLINK \l "fn12" \h [12] HYPERLINK \l "fn7" \h [7]

Chlorophyll and chlorophyllin around oral/oral biofilm
Natural photosensitizers for oral biofilm
A recent clinical study on antimicrobial photodynamic therapy for oral biofilm evaluated several natural photosensitizers, including chlorophyll derivatives, though the primary indication is periodontal disease rather than oral cancer. HYPERLINK \l "fn14" \h [14]
The rationale is that chlorophyll(‑in) can act as a photosensitizer, generating reactive oxygen species to modulate microbial biofilms and potentially alter local inflammatory microenvironments; this conceptually overlaps with antioxidant and pro‑inflammatory modulation axes important in oral carcinogenesis. HYPERLINK \l "fn14" \h [14] HYPERLINK \l "fn7" \h [7]
Wheatgrass and oral squamous cell carcinoma
A preprint on wheatgrass bioactives in oral squamous cell carcinoma suggests that wheatgrass juice/extract, rich in chlorophyll, flavonoids and antioxidant enzymes, may have protective effects against OSCC; however, data are preliminary and composition is characterized at a broad phytochemical level rather than precise ratios. HYPERLINK \l "fn5" \h [5]
The same document implies oral administration (juice, possibly lozenges or powders) as a dietary adjunct, not a regulated oral‑cancer formulation; chlorophyll content is high, but specific chlorophyllin, apigenin, quercetin or abscisic acid quantitation is not given. HYPERLINK \l "fn5" \h [5]

Abscisic acid: cancer‑relevant but not oral‑focused
Abscisic acid (ABA) is recognized as a plant hormone with emerging immunomodulatory and metabolic effects, and some oncology‑related pathways (e.g., PPARγ, inflammatory signaling) are being explored, but direct formulations targeting oral cancer with ABA are not visible in current mainstream PubMed or commercial data. HYPERLINK \l "fn7" \h [7]
ABA occasionally appears in broad “phytohormone” or plant‑stress extract discussions, but without explicit oral cavity indications or dosage‑form definition suitable for nutraceutical registration. HYPERLINK \l "fn7" \h [7]
Given this, ABA is a mechanistic interest rather than a component of any publicly documented oral‑cancer supplement or AYUSH formulation combining all your listed actives.

AYUSH / pharmacopoeial formulations
AYUSH and related ethnopharmacology literature list numerous herbal formulations for “blood purifier”, “anti‑oxidant”, “anti‑inflammatory” or “tumor” support that contain flavonoid‑rich plants (e.g., Azadirachta indica, Ocimum sanctum, Curcuma longa, green tea), some of which are relevant to head‑and‑neck cancers; however, publicly accessible monographs do not show formulations explicitly stated for “oral cancer” with chlorophyll/apigenin/quercetin/ABA all together. HYPERLINK \l "fn9" \h [9]
One extensive review of medicinal plants and polyherbal formulations relevant to human oral diseases notes quercetin as the main flavonoid in onions and discusses polyherbal formulations with activity on human oral tissue, but specific ingredient ratios, dosage forms and exact oral‑cancer indications are either unspecified or focused on general oral health. HYPERLINK \l "fn9" \h [9]

Polyherbal and combination concepts (near‑matches)
Sulforaphane–resveratrol–genistein oral strip (attached file)
Your attached discovery output describes a conceptual oral strip product for oral cancer containing sulforaphane (from crucifers), trans‑resveratrol and a genistein‑rich isoflavone fraction. HYPERLINK \l "fn10" \h [10]
Mechanistic target map includes Nrf2, p‑STAT3, NF‑κB, PI3K/Akt/mTOR, COX‑2, MMP‑9, EGFR/Src, VEGF and pro‑inflammatory cytokines IL‑6, TNF‑α, CXCL‑8, directly matching your mechanistic axes (antioxidant, cell‑cycle/survival signaling, pro‑inflammatory modulation). HYPERLINK \l "fn10" \h [10]
The proposed dosage form is an intra‑oral strip/film designed for localized mucosal exposure, with dose‑capping and labeling framed as “oral mucosal support” under Indian nutraceutical rules rather than a cancer treatment claim. HYPERLINK \l "fn10" \h [10]
Although this concept uses different actives, it is structurally similar to what you are exploring (oral strip, multi‑target phytochemicals, OSCC model, Nrf2/NF‑κB/STAT3/EGFR axis).

Commercial nutraceuticals and supplements
Mainstream global and Indian supplements containing chlorophyll/chlorophyllin are marketed for “detox”, bad breath and general antioxidant support, usually as liquids, tablets or capsules delivering ~50–300 mg chlorophyllin per day; cancer‑specific claims, particularly “oral cancer”, are typically avoided for regulatory reasons. HYPERLINK \l "fn7" \h [7]
Quercetin supplements (500–1000 mg/day) and apigenin‑containing products (often standardized chamomile or parsley extracts) are sold for general antioxidant and anti‑inflammatory support; oral cancer is not a labeled indication, though mechanistic reviews discuss their potential as adjuvant cancer therapeutics. HYPERLINK \l "fn3" \h [3] HYPERLINK \l "fn12" \h [12] HYPERLINK \l "fn7" \h [7]
Polyherbal “immune support” or “anti‑inflammatory” blends sometimes contain quercetin, rutin and chlorophyll‑rich ingredients (e.g., wheatgrass, alfalfa), but public labels rarely disclose precise mg ratios of each flavonoid, and no example could be found that prominently includes abscisic acid or explicitly mentions “oral cancer” as an indication. HYPERLINK \l "fn9" \h [9] HYPERLINK \l "fn7" \h [7]

Mechanistic summary for your four bioactives
Even though combined formulations are scarce, mechanistic evidence supports each component’s relevance to OSCC biology:
Apigenin: Induces cell‑cycle arrest (G2/M, G0/G1), triggers apoptosis, suppresses NF‑κB and PI3K/Akt, and exhibits strong antioxidant properties; oral administration reduces tumor burden in several preclinical models. HYPERLINK \l "fn1" \h [1] HYPERLINK \l "fn8" \h [8] HYPERLINK \l "fn6" \h [6] HYPERLINK \l "fn7" \h [7]
Quercetin / rutin: In OSCC and oral cancer models, quercetin reduces proliferation, invasion and metastasis, induces apoptosis, modulates PI3K/Akt and NF‑κB, and enhances chemosensitivity; rutin contributes to antioxidant and vascular effects. HYPERLINK \l "fn4" \h [4] HYPERLINK \l "fn12" \h [12] HYPERLINK \l "fn2" \h [2] HYPERLINK \l "fn3" \h [3] HYPERLINK \l "fn7" \h [7]
Chlorophyll / chlorophyllin: Acts as a photosensitizer in oral photodynamic therapy and provides antioxidant and potential DNA‑protective effects; wheatgrass‑derived chlorophyll is explored in OSCC, but data are early stage. HYPERLINK \l "fn14" \h [14] HYPERLINK \l "fn5" \h [5] HYPERLINK \l "fn7" \h [7]
Abscisic acid: Emerging data link ABA to modulation of immune and inflammatory pathways and metabolic regulation, which may intersect with cancer biology; however, specific oral‑cancer formulations or detailed OSCC data are minimal in current literature. HYPERLINK \l "fn7" \h [7]

Practical implications for your formulation work
Publicly reported formulations that simultaneously include chlorophyll(‑in), apigenin/flavonoids, quercetin/rutin and ABA with explicit oral‑cancer indication are not evident; you are likely in “first‑in‑class” territory and will need to build a rational design based on single‑molecule and partial combination data.
The most mature data for OSCC are around quercetin, apigenin and chlorophyll‑rich wheatgrass, plus conceptual oral strips (sulforaphane–resveratrol–genistein) with detailed mechanistic target maps; these can guide dose‑range selection, target pathways (Nrf2, NF‑κB, STAT3, PI3K/Akt, COX‑2, MMP‑9, EGFR) and choice of intra‑oral strip vs lozenge vs mouthwash delivery systems. HYPERLINK \l "fn6" \h [6] HYPERLINK \l "fn4" \h [4] HYPERLINK \l "fn5" \h [5] HYPERLINK \l "fn2" \h [2] HYPERLINK \l "fn14" \h [14] HYPERLINK \l "fn3" \h [3] HYPERLINK \l "fn10" \h [10] HYPERLINK \l "fn7" \h [7]
Would you like me to take the next step and draft a structured candidate formulation matrix (oral strip / mouthwash / lozenge) that combines chlorophyll(‑in), apigenin, quercetin/rutin and ABA with proposed mg ranges and mechanistic justification, tailored for an Indian nutraceutical/AYUSH‑compatible positioning?
⁂

Collect patents that include Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid with other botanicals or excipients for Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling. Extract claim sets and examples.Search Google Scholar and ClinicalTrials.gov for formulations of Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid evaluated in human or preclinical Oral Cancer models.Identify research articles where Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid are part of multi-herbal formulations; analyze mechanisms related to Oral Cancer.List formulations with Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid registered in traditional systems (Ayurveda/Siddha/Unani) addressing Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling.Extract composition, ratio, standardization markers, and dosage details from patents using Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling in Oral Cancer.
There are multiple patents and research articles that use apigenin, quercetin/rutin and broader flavonoid complexes with other botanicals/excipients for antioxidant, anti‑inflammatory and cell‑signaling modulation, but none that clearly combine all of chlorophyll(‑in), apigenin/flavonoids, quercetin/rutin and abscisic acid in a single claimed formulation for oral cancer; instead, your target molecules appear in overlapping but distinct composition families aimed at oxidative stress, inflammation, DNA repair and general cancer risk. HYPERLINK \l "fn17" \h [17] HYPERLINK \l "fn18" \h [18] HYPERLINK \l "fn19" \h [19] HYPERLINK \l "fn20" \h [20] HYPERLINK \l "fn21" \h [21] HYPERLINK \l "fn22" \h [22] HYPERLINK \l "fn23" \h [23] HYPERLINK \l "fn24" \h [24] HYPERLINK \l "fn25" \h [25]
Below is a structured overview of the most relevant patents, clinical/preclinical formulations and mechanistic articles, with emphasis on multi‑component compositions and what you can extract for an oral‑cancer‑focused design.

Key patents including apigenin / quercetin / rutin
1. Olive‑polyphenol–flavonoid compositions for pain/inflammation
WO2020095236A1 / US20200138843A1 – “Compositions comprising antioxidants for use in treating pain and inflammation”: These patents describe a pharmaceutical composition containing high levels of olive phenolics (oleuropein, hydroxytyrosol, tyrosol) plus flavonoids “such as, without limiting, rutin, quercetin, luteolin and apigenin,” with additional components like caffeic acid and oleocanthal. HYPERLINK \l "fn18" \h [18] HYPERLINK \l "fn17" \h [17]
The core claims cover antioxidant and anti‑inflammatory activity via modulation of NF‑κB and downstream cytokines (TNF‑α, IL‑1β, IL‑6), prostaglandin E2 and leukotrienes, which are directly relevant to pro‑inflammatory and cell‑signaling axes important in oral carcinogenesis, though oral cancer is not specified. HYPERLINK \l "fn17" \h [17] HYPERLINK \l "fn18" \h [18]
Claims include an oral dosage form (capsules, tablets, possibly oral liquids) with oleuropein present “from about” a defined percentage and high phenolic content; flavonoids (rutin, quercetin, apigenin, luteolin) are part of a synergistic antioxidant/anti‑inflammatory profile, but exact mg ratios between individual flavonoids are not fully quantified in the claims snippet. HYPERLINK \l "fn18" \h [18] HYPERLINK \l "fn17" \h [17]
Mechanistic relevance:
By combining olive phenolics and flavonoids, these compositions target NF‑κB, COX‑2, cytokines and oxidative stress – all key nodes in oral cancer progression (microenvironment, chronic inflammation, ROS‑driven DNA damage), making the patent useful as a mechanistic and excipient template even though the indication is pain/inflammation rather than OSCC. HYPERLINK \l "fn25" \h [25] HYPERLINK \l "fn17" \h [17] HYPERLINK \l "fn18" \h [18]

2. Bioflavonol mixtures – isoquercetin, quercetin, rutin
US6514527B1 / EP1319405A1 / WO2000025795A1 / US20030022845A1 – “Compositions comprising a mixture of bioflavonols”: These related patents cover food‑supplement compositions containing two or three bioflavonols such as isoquercetin, quercetin‑4′‑glycoside, rutin and quercetin. HYPERLINK \l "fn20" \h [20] HYPERLINK \l "fn21" \h [21] HYPERLINK \l "fn26" \h [26] HYPERLINK \l "fn27" \h [27]
The key claim is a composition comprising isoquercetin (or quercetin‑4‑glycoside), quercetin and rutin in a molar ratio of about 1 : 1.5 : 3, formulated for oral administration to maintain sustained plasma levels and protect tissues from oxidative damage. HYPERLINK \l "fn21" \h [21] HYPERLINK \l "fn26" \h [26] HYPERLINK \l "fn27" \h [27] HYPERLINK \l "fn20" \h [20]
The patents explicitly discuss reactive oxygen species in the aetiology of diseases including cancer, and position these flavonols as dietary antioxidants that support endogenous defenses, but they do not narrow the indication to oral cancer. HYPERLINK \l "fn26" \h [26] HYPERLINK \l "fn27" \h [27] HYPERLINK \l "fn20" \h [20] HYPERLINK \l "fn21" \h [21]
Mechanistic and formulation insight:
These patents give you a rare, explicit ratio blueprint for a quercetin–rutin–isoquercetin blend aimed at antioxidant protection, which is transferable to OSCC chemopreventive concepts (e.g., oral strip or mouthwash flavonoid layer). HYPERLINK \l "fn27" \h [27] HYPERLINK \l "fn20" \h [20] HYPERLINK \l "fn21" \h [21] HYPERLINK \l "fn26" \h [26] HYPERLINK \l "fn25" \h [25]
Oral dosage forms are food supplements (capsules, tablets, powders), and the pharmacokinetic rationale—different absorption and half‑life for each flavonol—could be adapted for sustained local mucosal exposure or systemic coverage in oral cancer. HYPERLINK \l "fn20" \h [20] HYPERLINK \l "fn21" \h [21]

3. Multi‑component oxidative‑stress/DNA‑repair compositions
US20260090969A1 / US20210267870A1 / WO2020012175A1 – “Compositions that protect cells from oxidative and mitochondrial stress”: These patents claim oral or topical compositions aimed at enhancing cell resistance to DNA damage, oxidative stress and mitochondrial dysfunction, with relevance to ageing and cancer risk. HYPERLINK \l "fn19" \h [19] HYPERLINK \l "fn22" \h [22] HYPERLINK \l "fn23" \h [23]
The claims include formulations containing niacinamide (150–700 mg), quercetin or rutin (150–700 mg), zinc, ascorbic acid and parsley or its derivative apigenin (1–1000 mg), forming a multi‑nutrient composition that improves DNA repair capacity and oxidative resilience. HYPERLINK \l "fn19" \h [19]
The broader component list used in various embodiments includes apigenin, quercetin, rutin, chamomile, astragalus, curcumin, Bacopa monnieri and others, providing a large herbal/nutrient space for antioxidant and signaling modulation; again, oral cancer is not the specified indication but cancer is mentioned as an age‑related disease. HYPERLINK \l "fn22" \h [22] HYPERLINK \l "fn23" \h [23] HYPERLINK \l "fn19" \h [19]
Mechanistic and dosage details:
Mechanistic narrative focuses on protecting DNA, improving repair, and resisting oxidative/mitochondrial stress—highly relevant to oral mucosa exposed to tobacco, alcohol and chronic irritation in OSCC. HYPERLINK \l "fn23" \h [23] HYPERLINK \l "fn22" \h [22] HYPERLINK \l "fn25" \h [25] HYPERLINK \l "fn19" \h [19]
The numeric ranges in claims (e.g., 150–700 mg quercetin/rutin; up to 1000 mg apigenin‑equivalent from parsley) give a human‑dose frame for oral antioxidant formulations that you can map onto OSCC targets and delivery systems (oral strip, lozenge, mouthwash). HYPERLINK \l "fn19" \h [19]

4. Natural‑preservative blends featuring apigenin, quercetin, rutin
WO2023150694A1 – “Natural preservatives and uses thereof”: This patent covers compositions with two or more natural preservatives selected from rosmarinic acid, dihydroquercetin, kaempferol, caffeic acid, apigenin, ferulic acid, rutin, quercetin and others, designed to preserve food or beverages. HYPERLINK \l "fn24" \h [24]
While the immediate use is food preservation, the patent frames these molecules as antioxidant and antimicrobial agents, often overlapping with anti‑inflammatory and cell‑signaling pathways relevant to oral cancer (e.g., ROS scavenging, NF‑κB and MAPK modulation). HYPERLINK \l "fn24" \h [24] HYPERLINK \l "fn25" \h [25]
Relevance to your brief:
This patent demonstrates recognized synergy of apigenin, quercetin and rutin in multiphytochemical systems and may inform excipient choices (e.g., plant extracts that provide these actives concurrently) in an OSCC‑focused nutraceutical, even though it does not address cancer or oral mucosa directly. HYPERLINK \l "fn25" \h [25] HYPERLINK \l "fn24" \h [24]

Patents mentioning abscisic acid and chlorophyll
Within the patent set identified above, abscisic acid and chlorophyll/chlorophyllin do not appear explicitly in the claims snippets for the main apigenin–quercetin–rutin–olive phenolic or DNA‑repair compositions; ABA is more common in agricultural/plant physiology patents than human nutraceutical formulations, and chlorophyll(‑in) appears mostly in food colorant or photodynamic therapy contexts not linked to OSCC in the current patent sample. HYPERLINK \l "fn22" \h [22] HYPERLINK \l "fn23" \h [23] HYPERLINK \l "fn24" \h [24] HYPERLINK \l "fn25" \h [25] HYPERLINK \l "fn19" \h [19]
This suggests that any OSCC‑focused multi‑herbal product combining chlorophyll, apigenin, quercetin/rutin and ABA would be largely novel, with existing patents serving only as partial prior art for antioxidant/anti‑inflammatory and DNA‑repair mechanisms rather than disease‑specific compositions. HYPERLINK \l "fn21" \h [21] HYPERLINK \l "fn23" \h [23] HYPERLINK \l "fn20" \h [20] HYPERLINK \l "fn22" \h [22] HYPERLINK \l "fn24" \h [24] HYPERLINK \l "fn25" \h [25] HYPERLINK \l "fn19" \h [19]

Clinical and preclinical formulations in oral cancer
Quercetin chemoprevention trial
NCT03476330 – “Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia”: An open‑label, single‑arm clinical trial uses oral quercetin as a dietary supplement to prevent or delay squamous cell carcinoma, including lesions in the oral cavity. HYPERLINK \l "fn28" \h [28]
The primary endpoint is reduction of buccal micronuclei as a surrogate marker of DNA damage and SCC susceptibility, linking quercetin’s antioxidant and DNA‑repair modulation roles to oral mucosal carcinogenesis. HYPERLINK \l "fn28" \h [28]
While the trial focuses on high‑risk Fanconi anemia patients and uses quercetin alone (no apigenin/chlorophyll/ABA), it provides clinical evidence and dosing context for flavonoid‑based chemoprevention in oral tissues. HYPERLINK \l "fn29" \h [29] HYPERLINK \l "fn28" \h [28]
Quercetin nanoformulations and OSCC models
Multiple preclinical articles report quercetin in OSCC cell lines and xenografts, often as single‑compound formulations or nanoparticles:
Quercetin suppresses OSCC tumorigenesis via miR‑22/WNT1/β‑catenin axis, reducing viability and promoting apoptosis in vitro and inhibiting xenograft growth in vivo. HYPERLINK \l "fn30" \h [30]
Tongue SCC models show quercetin‑induced apoptosis, cell‑cycle arrest and anti‑metastatic effects via modulation of key pathways such as NF‑κB, PI3K/Akt and p53, with strong antioxidant components. HYPERLINK \l "fn31" \h [31] HYPERLINK \l "fn25" \h [25]
Systematic reviews emphasize quercetin’s multi‑targeting potential and advocate clinical trials and targeted delivery systems (e.g., nanoparticles) for oral cancer therapy. HYPERLINK \l "fn32" \h [32] HYPERLINK \l "fn33" \h [33] HYPERLINK \l "fn34" \h [34] HYPERLINK \l "fn25" \h [25]
Apigenin in OSCC
A pivotal study showed that apigenin impairs oral squamous cell carcinoma growth (SCC‑25 cell line), inducing apoptosis and cell‑cycle arrest at both G0/G1 and G2/M, with decreased cyclin D1/E and inactivation of CDK1. HYPERLINK \l "fn35" \h [35]
This directly supports apigenin’s role in cell‑cycle arrest and pro‑apoptotic signaling in oral cancer cells, aligning with the mechanistic axes you specified. HYPERLINK \l "fn36" \h [36] HYPERLINK \l "fn37" \h [37] HYPERLINK \l "fn35" \h [35] HYPERLINK \l "fn25" \h [25]
Rutin and oral cancer
Recent work indicates rutin has anticancer activity in oral cancer, with computational and experimental data showing modulation of PI3K/Akt, MAPK and NF‑κB pathways, reduction of cell viability, and induction of caspase‑mediated apoptosis. HYPERLINK \l "fn38" \h [38] HYPERLINK \l "fn39" \h [39]
Rutin’s pharmacokinetic profile suggests favorable absorption and bioavailability, supporting its inclusion in multi‑herbal OSCC formulations for antioxidant and signaling modulation. HYPERLINK \l "fn39" \h [39] HYPERLINK \l "fn25" \h [25]
Chlorophyll / wheatgrass / oral bioactives
Wheatgrass bioactives, rich in chlorophyll and flavonoids, have been explored in OSCC models, suggesting antioxidant and cytoprotective effects, though data are at preprint stage and formulations are more like juices or crude extracts rather than standardized nutraceuticals. HYPERLINK \l "fn40" \h [40]
Natural photosensitizer studies in oral biofilm and aPDT mention chlorophyll derivatives used for oral mucosal applications, indirectly connecting chlorophyll to ROS modulation in oral tissues, but not yet to formal oral‑cancer formulations. HYPERLINK \l "fn41" \h [41] HYPERLINK \l "fn25" \h [25]

Multi‑herbal formulations and traditional systems
Reviews of bioactive phytocompounds for oral cancer prevention and treatment summarize multiple plants (green tea, turmeric, neem, bitter gourd, wheatgrass, chamomile, parsley, onions) that provide apigenin, quercetin/rutin and chlorophyll‑rich matrices, acting on antioxidant, NF‑κB, STAT3, PI3K/Akt and other pathways; however, they predominantly discuss research extracts and conceptual formulations, not registered AYUSH/Siddha/Unani products with explicit OSCC indications. HYPERLINK \l "fn42" \h [42] HYPERLINK \l "fn43" \h [43] HYPERLINK \l "fn25" \h [25]
AYUSH monographs and ethnopharmacology documents mention many antioxidant and “tumour” formulations, but publicly accessible sources do not clearly show standardised polyherbal products that list chlorophyll/chlorophyllin, apigenin, quercetin/rutin and abscisic acid together with explicit oral‑cancer indication and detailed composition ratios. HYPERLINK \l "fn43" \h [43] HYPERLINK \l "fn25" \h [25]

What can be extracted for composition/ratio and mechanism
From the patents and articles above you can pull the following actionable elements for an oral‑cancer‑oriented formulation strategy:
Quercetin–rutin–isoquercetin ratio: 1 : 1.5 : 3 (molar) from the bioflavonol patents, used for sustained antioxidant coverage and tissue protection; adaptable to oral strip, lozenge or mouthwash flavonoid layers. HYPERLINK \l "fn26" \h [26] HYPERLINK \l "fn27" \h [27] HYPERLINK \l "fn20" \h [20] HYPERLINK \l "fn21" \h [21]
Quercetin/apigenin–zinc–niacinamide ranges: 150–700 mg quercetin or rutin, 150–700 mg niacinamide, 1–1000 mg parsley/apigenin, plus vitamin C and zinc, documented for DNA‑repair enhancement and oxidative stress protection; this gives a human‑dose frame and a mechanistic bundle for genomic stability relevant to oral cancer. HYPERLINK \l "fn23" \h [23] HYPERLINK \l "fn22" \h [22] HYPERLINK \l "fn25" \h [25] HYPERLINK \l "fn19" \h [19]
Olive‑polyphenol plus flavonoids: High oleuropein and hydroxytyrosol with quercetin, rutin and apigenin, aimed at NF‑κB and cytokine suppression; useful as a model for anti‑inflammatory and cell‑signaling modulation in OSCC, especially for chronic mucosal inflammation. HYPERLINK \l "fn17" \h [17] HYPERLINK \l "fn18" \h [18] HYPERLINK \l "fn25" \h [25]
Mechanistic anchors:
Apigenin: G0/G1 and G2/M arrest, cyclin/CDK modulation, apoptosis in SCC‑25 OSCC cells. HYPERLINK \l "fn35" \h [35]
Quercetin: miR‑22/WNT1/β‑catenin axis, NF‑κB, PI3K/Akt, MAPK, p53, anti‑metastatic and chemosensitizing effects in OSCC. HYPERLINK \l "fn33" \h [33] HYPERLINK \l "fn34" \h [34] HYPERLINK \l "fn32" \h [32] HYPERLINK \l "fn30" \h [30] HYPERLINK \l "fn31" \h [31] HYPERLINK \l "fn25" \h [25]
Rutin: PI3K/Akt, MAPK, NF‑κB modulation, caspase activation, antioxidant and anti‑inflammatory activity in oral cancer cell models. HYPERLINK \l "fn38" \h [38] HYPERLINK \l "fn39" \h [39] HYPERLINK \l "fn25" \h [25]
Chlorophyll/wheatgrass: antioxidant, ROS modulation, potential DNA damage reduction in oral mucosa; more preliminary but mechanistically aligned. HYPERLINK \l "fn40" \h [40] HYPERLINK \l "fn41" \h [41] HYPERLINK \l "fn25" \h [25]
Abscisic acid, while mechanistically interesting (immune and inflammatory modulation), currently lacks clear patents or clinical formulations in oral cancer; you would likely need to rely on broader immunometabolic literature and design ABA as an innovative add‑on rather than a re‑use of existing OSCC‑specific art. HYPERLINK \l "fn25" \h [25]

Would you like me to synthesise these data points into a candidate patent‑style claim set and example formulations (e.g., oral strip, lozenge, mouthwash) that combine chlorophyll(‑in), apigenin, quercetin/rutin and optional ABA with defined mg ranges, ratios and mechanistic language suitable for an oral‑cancer‑support nutraceutical concept?
⁂

Identify formulations pairing Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid with known bioenhancers (e.g., piperine) to improve efficacy or bioavailability in Oral Cancer.Find nutraceutical brands using Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling; summarize formulation ingredients and labeling claims for Oral Cancer.Map excipients and stabilizers used in marketed formulations involving Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for Oral Cancer.Identify patents describing extraction or standardization methods for Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid under Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling mechanisms.Compare similar formulations using different extraction solvents for Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid targeting Oral Cancer. Provide pros/cons.
Formulations specifically pairing chlorophyll(‑in), apigenin, quercetin/rutin or abscisic acid with classic bioenhancers like piperine for oral cancer are not yet visible as marketed nutraceuticals or AYUSH products; instead, piperine–quercetin combinations and nano‑delivery systems are being explored at the preclinical level for OSCC, while most commercial brands use these actives for broad antioxidant/immune support without oral‑cancer labeling. HYPERLINK \l "fn47" \h [47] HYPERLINK \l "fn48" \h [48] HYPERLINK \l "fn49" \h [49] HYPERLINK \l "fn50" \h [50] HYPERLINK \l "fn51" \h [51] HYPERLINK \l "fn52" \h [52]
Below I’ll map what does exist and how you can leverage it for your design: bioenhancer pairings, excipients/stabilizers, extraction/standardization trends, and solvent pros/cons.

Bioenhancer pairings relevant to oral cancer
Quercetin + piperine in OSCC
A nanostructured lipid carrier (NLC) system co‑encapsulating quercetin and piperine has been tested in FaDu oral squamous carcinoma cells. HYPERLINK \l "fn48" \h [48] HYPERLINK \l "fn49" \h [49]
The NLCs (particle size <180 nm, PDI <0.3) showed >85% entrapment efficiency for both drugs, improved release versus free quercetin/piperine, and significantly enhanced apoptosis, mitochondrial membrane depolarisation and cytotoxicity in FaDu cells compared to individual drugs. HYPERLINK \l "fn49" \h [49]
In vivo biodistribution in rats confirmed efficient distribution throughout the oral cavity after oral administration, indicating that lipid‑based dual‑drug NLCs can serve as a delivery platform for OSCC‑relevant phytochemicals plus bioenhancers. HYPERLINK \l "fn49" \h [49]
Piperine as broad bioavailability enhancer
Piperine is recognized as a global bioavailability enhancer by inhibiting efflux transporters (P‑gp) and cytochrome P450 enzymes, thereby increasing oral absorption of many drugs and phytochemicals; this has been demonstrated with curcumin and quercetin among others. HYPERLINK \l "fn53" \h [53] HYPERLINK \l "fn54" \h [54] HYPERLINK \l "fn55" \h [55] HYPERLINK \l "fn47" \h [47]
Spice‑derived nutraceuticals mapping show piperine, apigenin, quercetin and sulforaphane all acting on overlapping targets: NF‑κB, TNF‑α, IL‑1β, IL‑6, cyclin D1, MMPs and other hallmarks of inflammation and tumorigenesis, providing mechanistic justification for combining piperine with your flavonoids in oral‑cancer‑focused formulations. HYPERLINK \l "fn54" \h [54] HYPERLINK \l "fn55" \h [55] HYPERLINK \l "fn53" \h [53]
Piperine has also been shown to enhance cisplatin’s anticancer effects in tongue SCC models, supporting the concept of piperine as an adjunct modulator of drug and phytochemical efficacy in oral cavity cancers. HYPERLINK \l "fn56" \h [56]
Implication for your matrix:
While apigenin and chlorophyll(‑in) have not yet been widely paired with piperine specifically in OSCC literature, the strong quercetin–piperine NLC data and piperine’s demonstrated effects on inflammatory and proliferative pathways suggest that apigenin–quercetin–piperine combinations in an oral strip or lozenge are mechanistically sound. HYPERLINK \l "fn55" \h [55] HYPERLINK \l "fn48" \h [48] HYPERLINK \l "fn53" \h [53] HYPERLINK \l "fn54" \h [54] HYPERLINK \l "fn49" \h [49]

Nutraceutical brands and labeling (oral cancer vs general support)
Reviews and clinical/scientific articles emphasise quercetin’s potential in oral cancer, but commercially available quercetin supplements (capsules, tablets, powders) typically claim antioxidant, immune support, anti‑inflammatory or cardiovascular health, rarely “oral cancer” due to regulatory constraints. HYPERLINK \l "fn50" \h [50] HYPERLINK \l "fn51" \h [51] HYPERLINK \l "fn52" \h [52]
Piperine–curcumin and quercetin–piperine blends are marketed for enhanced bioavailability and general inflammation/oxidative stress, often referencing NF‑κB and cytokine modulation in promotional literature, but again avoid cancer‑specific language. HYPERLINK \l "fn57" \h [57] HYPERLINK \l "fn47" \h [47] HYPERLINK \l "fn54" \h [54] HYPERLINK \l "fn55" \h [55]
Chlorophyll/chlorophyllin supplements (including wheatgrass powders and liquids) are labeled for “detox”, antioxidant activity, and oral hygiene (bad breath, oral freshness), not OSCC, even though mechanistic reviews highlight ROS modulation in oral tissues. HYPERLINK \l "fn52" \h [52] HYPERLINK \l "fn58" \h [58]
Abscisic acid does not feature prominently in mainstream nutraceutical brand ingredient lists for cancer or oral health; its presence is mainly in research contexts rather than consumer formulations. HYPERLINK \l "fn52" \h [52]
Takeaway:
You are working in a space where mechanistic support exists, but regulatory practice discourages direct “oral cancer” claims; most brands frame these ingredients around antioxidant and inflammatory pathways, which you can mirror while designing OSCC‑oriented science narratives in dossiers and academic publications.

Excipients and stabilizers in relevant formulations
Nanostructured lipid carriers (quercetin + piperine)
The quercetin–piperine NLC system uses a lipid matrix (solid and liquid lipids) formed via high‑shear homogenisation, with typical excipient classes including triglycerides or fatty acid esters, surfactants (e.g., polysorbates, phospholipids) and cryoprotectants for lyophilisation. HYPERLINK \l "fn48" \h [48] HYPERLINK \l "fn49" \h [49]
Differential scanning calorimetry and XRD showed conversion into an amorphous matrix, indicating that excipient selection stabilizes quercetin and piperine in a less crystalline, more bioaccessible form—critical for hydrophobic flavonoids. HYPERLINK \l "fn59" \h [59] HYPERLINK \l "fn49" \h [49]
Curcumin–piperine and curcumin–quercetin nanoformulations
Dual‑drug nanoparticle systems for curcumin plus piperine/quercetin use PLGA or similar biodegradable polymers, often with stabilizers such as PVA, lecithin and PEG‑based surfactants, to improve solubility and protect against hydrolysis and photodegradation. HYPERLINK \l "fn57" \h [57] HYPERLINK \l "fn59" \h [59]
Compatibility and solid‑state studies emphasise avoiding excipients that accelerate curcumin’s or quercetin’s degradation (e.g., strong oxidants, certain sugars), suggesting analogous caution for apigenin and chlorophyllin in oral‑strip or lozenge bases. HYPERLINK \l "fn59" \h [59]
Typical excipients in flavonoid nutraceuticals
From broader flavonoid and quercetin nanoformulation reviews:
Solubility enhancers: cyclodextrins, phospholipids, co‑solvents (ethanol, propylene glycol), and surfactants. HYPERLINK \l "fn60" \h [60] HYPERLINK \l "fn50" \h [50] HYPERLINK \l "fn52" \h [52]
Stabilizers/antioxidants: natural tocopherols, ascorbyl palmitate, citric acid, to protect flavonoids from oxidation. HYPERLINK \l "fn59" \h [59] HYPERLINK \l "fn52" \h [52]
Film/strip bases (for oral delivery): hydroxypropyl methylcellulose, pullulan, gelatin, plasticizers such as glycerol or sorbitol; these can be adapted to carry quercetin, apigenin and chlorophyllin with piperine as bioenhancer. HYPERLINK \l "fn61" \h [61] HYPERLINK \l "fn52" \h [52]

Extraction/standardization patents and methods
Even though the current patent sample we looked at does not spell out detailed chlorophyll/apigenin/quercetin extraction methods, general trends for your actives are:
Quercetin/rutin: Often standardized from Sophora japonica, onions, citrus or seed extracts using hydroalcoholic or ethanolic extraction followed by purification (e.g., chromatographic enrichment); patents on bioflavonol mixtures imply high‑purity isoquercetin/quercetin/rutin ratios but focus more on composition than process. HYPERLINK \l "fn62" \h [62] HYPERLINK \l "fn63" \h [63] HYPERLINK \l "fn64" \h [64] HYPERLINK \l "fn65" \h [65] HYPERLINK \l "fn52" \h [52]
Apigenin: Typically obtained from parsley, chamomile or celery using ethanol or methanol–water mixtures, with follow‑up fractionation; mechanistic reviews highlight its presence in Chinese medicinal herbs and dietary plants but do not detail solvent patents. HYPERLINK \l "fn66" \h [66] HYPERLINK \l "fn67" \h [67] HYPERLINK \l "fn52" \h [52]
Chlorophyll/chlorophyllin: Extracted from green leafy plants (wheatgrass, alfalfa, spinach) usually with organic solvents (acetone, ethanol) and saponification/metal substitution to yield sodium/copper chlorophyllin; food colorant patents and industrial monographs describe these processes. HYPERLINK \l "fn58" \h [58] HYPERLINK \l "fn52" \h [52]
Abscisic acid: Isolated from plant materials or produced synthetically; most process patents focus on agricultural applications, not oral‑cancer nutraceuticals. HYPERLINK \l "fn52" \h [52]
Mechanistically, all these extraction methods aim to preserve antioxidant and signaling activity, but OSCC‑specific claims about extraction/standardization are not yet common.

Solvent choices: pros and cons for oral‑cancer applications
For chlorophyll(‑in), apigenin, quercetin/rutin and ABA extracts, the main solvent families are:
Hydroalcoholic/ethanolic extracts
Pros:
Good solubility for flavonoids (quercetin, apigenin, rutin) and many phenolics. HYPERLINK \l "fn50" \h [50] HYPERLINK \l "fn52" \h [52]
Widely accepted in nutraceutical manufacturing; easier to dry onto films/strips or compress into lozenges/tablets. HYPERLINK \l "fn52" \h [52]
Often preserve antioxidant capacity and maintain polyphenol profiles relevant to NF‑κB, PI3K/Akt, MAPK and cell‑cycle modulation. HYPERLINK \l "fn53" \h [53] HYPERLINK \l "fn52" \h [52]
Cons:
Chlorophyll can be less stable in ethanol under light and heat; risk of degradation and color changes if not protected. HYPERLINK \l "fn58" \h [58] HYPERLINK \l "fn59" \h [59]
Some residual solvent limits and flavour considerations for oral strips/mouthwashes, particularly in Indian regulatory context.
Aqueous extracts
Pros:
Safer for mouthwash and pediatric formulations; better regulatory acceptance and sensory profiles. HYPERLINK \l "fn68" \h [68] HYPERLINK \l "fn52" \h [52]
Suitable for chlorophyll‑rich juices (e.g., wheatgrass) and some glycosylated flavonoids like rutin. HYPERLINK \l "fn68" \h [68] HYPERLINK \l "fn58" \h [58]
Cons:
Lower solubility for aglycones (quercetin, apigenin); may require co‑solvents or micellar/nano‑systems to achieve effective OSCC dosing. HYPERLINK \l "fn60" \h [60] HYPERLINK \l "fn50" \h [50]
Greater microbial risk, requiring preservatives (which might interact with bioactives).
Lipid‑based systems (NLCs, nanoemulsions)
Pros:
Excellent for hydrophobic flavonoids and piperine; improved solubility, stability and oral bioavailability, as shown in quercetin–piperine NLCs. HYPERLINK \l "fn48" \h [48] HYPERLINK \l "fn49" \h [49]
Enable targeted deposition in oral mucosa, with good entrapment efficiency and controlled release. HYPERLINK \l "fn49" \h [49]
Cons:
More complex manufacturing; need careful excipient selection to avoid off‑target effects and ensure safety for daily use. HYPERLINK \l "fn59" \h [59] HYPERLINK \l "fn52" \h [52]
May be less suitable for high‑chlorophyll content unless specifically engineered.
Supercritical CO₂ and advanced extraction
Pros:
Produce solvent‑free, concentrated extracts of lipophilic components (quercetin aglycone, apigenin, chlorophyll), potentially with cleaner profiles. HYPERLINK \l "fn52" \h [52]
High stability and purity; good fit for premium OSCC nutraceutical concepts.
Cons:
Higher cost; limited Indian manufacturing capacity compared to hydroalcoholic extraction.
Requires more detailed process validation for regulatory acceptance.

How this informs an oral‑cancer formulation strategy
Based on the evidence:
Bioenhancers: Piperine is the most validated bioenhancer to pair with quercetin in oral cancer research, with strong in vitro OSCC data and mechanistic synergy across NF‑κB, cytokines, MMPs and apoptosis. Extending this to apigenin and possibly chlorophyllin in an intra‑oral delivery system is scientifically defensible. HYPERLINK \l "fn54" \h [54] HYPERLINK \l "fn55" \h [55] HYPERLINK \l "fn53" \h [53] HYPERLINK \l "fn48" \h [48] HYPERLINK \l "fn49" \h [49]
Brands and claims: To remain regulatory‑compliant, an OSCC‑support formulation would likely be labeled around “antioxidant support,” “oral mucosal health,” “anti‑inflammatory support” and “cellular protection,” with oral cancer mechanisms documented in technical monographs rather than on consumer labels. HYPERLINK \l "fn51" \h [51] HYPERLINK \l "fn50" \h [50] HYPERLINK \l "fn52" \h [52]
Excipients: Lipid matrices, cyclodextrins, film‑forming polymers and stabilising antioxidants are common in advanced quercetin/piperine systems and can be adapted for chlorophyllin and apigenin; excipient compatibility studies (like those for curcumin) should be replicated. HYPERLINK \l "fn57" \h [57] HYPERLINK \l "fn49" \h [49] HYPERLINK \l "fn59" \h [59]
Extraction/solvents: For an Indian OSCC nutraceutical, hydroalcoholic extracts of apigenin‑ and quercetin‑rich plants plus a stabilised chlorophyllin fraction, possibly combined with lipid‑based nanocarriers and piperine, likely offer the best balance between efficacy, manufacturability and regulatory practicality. HYPERLINK \l "fn58" \h [58] HYPERLINK \l "fn68" \h [68] HYPERLINK \l "fn49" \h [49] HYPERLINK \l "fn52" \h [52]
Would you like me to draft a concrete formulation blueprint (e.g., an oral strip or mouthwash) listing: plant sources, extraction solvent, standardization markers (mg of apigenin/quercetin/chlorophyllin), piperine dose, and excipient system tailored to OSCC biology and Indian nutraceutical rules?
⁂

Identify clinical formulations combining Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid with vitamins or minerals for Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling in Oral Cancer.Analyze dosage and delivery systems (capsules, emulsions, patches, gels) for formulations using Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid.Collect formulations containing Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid combined with probiotics or prebiotics supporting Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling outcomes.Identify nano- or liposomal formulations reported for Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid in Oral Cancer therapy; summarize particle size & stability data.Search pharmacological reviews summarizing multi-component formulations for Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling in Oral Cancer using Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid.
Clinical formulations that combine your target phytochemicals with vitamins/minerals and are explicitly relevant to oral cancer are limited, but quercetin-centered clinical and review evidence is strongest; apigenin has the best nano-delivery review support, while chlorophyllin and abscisic acid remain mostly preclinical or non-oral-cancer-specific. HYPERLINK \l "fn71" \h [71] HYPERLINK \l "fn72" \h [72] HYPERLINK \l "fn73" \h [73] HYPERLINK \l "fn74" \h [74] HYPERLINK \l "fn75" \h [75]
Clinical and review-backed pairs
Quercetin + vitamins/minerals: the strongest directly relevant clinical framework is quercetin used as an oral chemopreventive agent in squamous cell carcinoma risk settings, with reviews emphasizing poor absorption and the need for nanoformulations; patent literature also shows quercetin/rutin combined with niacinamide, zinc and vitamin C for DNA-repair and oxidative-stress protection. HYPERLINK \l "fn76" \h [76] HYPERLINK \l "fn77" \h [77] HYPERLINK \l "fn78" \h [78] HYPERLINK \l "fn79" \h [79] HYPERLINK \l "fn80" \h [80]
Apigenin + delivery enhancers: apigenin reviews describe anti-cancer actions via apoptosis, cell-cycle arrest and signaling modulation, and note that nanoformulations are used to address low solubility and poor bioavailability; an apigenin–cyclodextrin nanoliposome-in-gel system is a clear example of a clinically oriented delivery concept, though it was developed for colon cancer rather than oral cancer. HYPERLINK \l "fn73" \h [73] HYPERLINK \l "fn74" \h [74] HYPERLINK \l "fn75" \h [75]
Chlorophyllin + oral health: chlorophyll-derived products appear more often in oral hygiene or photodynamic contexts than in oral cancer trials; I did not find a robust clinical oral-cancer formulation combining chlorophyllin with vitamins/minerals in the sources retrieved here. HYPERLINK \l "fn81" \h [81] HYPERLINK \l "fn82" \h [82] HYPERLINK \l "fn83" \h [83]
Dosage forms seen
Capsules/tablets: common for quercetin, rutin and apigenin supplement-style products, especially when paired with vitamins/minerals such as niacinamide, zinc and vitamin C. HYPERLINK \l "fn78" \h [78] HYPERLINK \l "fn79" \h [79] HYPERLINK \l "fn80" \h [80] HYPERLINK \l "fn76" \h [76]
Nanoemulsions / liposomes / nanoparticles: frequently used to improve quercetin and apigenin bioavailability; reviews specifically highlight liposomes and polymeric nanoparticles for oral cancer-relevant quercetin and apigenin. HYPERLINK \l "fn72" \h [72] HYPERLINK \l "fn74" \h [74] HYPERLINK \l "fn75" \h [75]
Gels / in situ gels: apigenin has been formulated as nanoliposomes in an in situ gel for oral administration, showing how a local mucosal or GI-stable system can be built around a flavonoid. HYPERLINK \l "fn73" \h [73]
Oral strips / lozenges / patches: I did not find a clinical oral-cancer formulation in the retrieved sources that uses these dosage forms with your exact ingredient set, but the mechanistic rationale is consistent with local-mucosal delivery concepts already used for flavonoids. HYPERLINK \l "fn74" \h [74] HYPERLINK \l "fn83" \h [83] HYPERLINK \l "fn72" \h [72]
Vitamins and minerals
Niacinamide, zinc, and vitamin C are the clearest documented mineral/vitamin partners in a multi-component flavonoid composition that includes quercetin/rutin and apigenin (via parsley). HYPERLINK \l "fn79" \h [79] HYPERLINK \l "fn80" \h [80] HYPERLINK \l "fn78" \h [78]
The stated goals are enhancing cell resistance to DNA damage, oxidative stress, mitochondrial dysfunction, and improving DNA repair capacity, which overlaps with the antioxidant and cell-signaling mechanisms you asked about. HYPERLINK \l "fn80" \h [80] HYPERLINK \l "fn78" \h [78] HYPERLINK \l "fn79" \h [79]
These formulations are not oral-cancer-labeled products, but they are the best documented multi-ingredient combinations in the patent corpus that map to your target biology. HYPERLINK \l "fn78" \h [78] HYPERLINK \l "fn79" \h [79] HYPERLINK \l "fn80" \h [80]
Probiotics and prebiotics
In the oral-cancer literature retrieved here, probiotics are mainly discussed for oral mucositis and microbiome balance, not as direct co-formulants with quercetin/apigenin/chlorophyllin. HYPERLINK \l "fn84" \h [84]
I did not find a validated formulation pairing your target phytochemicals with a probiotic or prebiotic that is specifically tested in oral cancer. HYPERLINK \l "fn84" \h [84]
For product design, probiotics may still be useful as an adjunct layer for inflammation control and mucosal tolerance, but that is a formulation hypothesis rather than a documented oral-cancer product claim. HYPERLINK \l "fn84" \h [84]
Nano and liposomal systems
Quercetin: reviews say nanoformulations improve stability, bioavailability, and therapeutic action in oral cancer; the therapeutic promise is tied to apoptosis, metastasis suppression, cell-cycle arrest, and chemosensitization. HYPERLINK \l "fn85" \h [85] HYPERLINK \l "fn71" \h [71] HYPERLINK \l "fn72" \h [72]
Apigenin: nano-therapeutic systems are explicitly recommended because they improve solubility, absorption, and tumor targeting; the review notes modulation of angiogenesis, apoptosis, metastasis, autophagy, cell cycle, and immune responses. HYPERLINK \l "fn75" \h [75] HYPERLINK \l "fn74" \h [74]
Particle-size/stability data: the clearest quantitative oral-cancer-relevant nano data retrieved here were for the quercetin–piperine NLC system described earlier; for apigenin, the current retrieved sources are review-level rather than detailed oral-cancer particle datasets. HYPERLINK \l "fn86" \h [86] HYPERLINK \l "fn87" \h [87] HYPERLINK \l "fn74" \h [74] HYPERLINK \l "fn75" \h [75]
Practical formulation map
Ingredient set
Vitamin/mineral partner
Delivery system
Oral-cancer relevance
Quercetin / rutin
Niacinamide, zinc, vitamin C
Capsules/tablets
Best documented patent-style DNA-protection and antioxidant support [78][79][80]
Apigenin
Vitamin C or cyclodextrin-compatible coformulation
Nano-liposomes, nanoparticles, in situ gels
Strong preclinical anti-cancer and delivery rationale [73][74][75]
Chlorophyllin
Vitamin C, antioxidant blends
Liquids/capsules
Mostly oral-health or photodynamic use; weak direct OSCC evidence [81][82]
Probiotic adjunct
Prebiotic fiber
Oral-care adjunct or tolerance support
Symptom/microbiome support rather than direct OSCC therapy [84]
Review-level synthesis
Reviews converge on the same mechanisms for your target compounds: antioxidant defense, cell-cycle arrest, apoptosis, and signal-pathway modulation (NF-κB, PI3K/Akt, WNT/β-catenin, and related cascades). HYPERLINK \l "fn72" \h [72] HYPERLINK \l "fn74" \h [74] HYPERLINK \l "fn75" \h [75]
For an oral-cancer-oriented formulation, the best-supported architecture is a quercetin/apigenin base, optionally with rutin and a vitamin/mineral antioxidant scaffold, delivered as a nanoparticle, liposome, or local oral gel/lozenge. HYPERLINK \l "fn71" \h [71] HYPERLINK \l "fn74" \h [74] HYPERLINK \l "fn75" \h [75] HYPERLINK \l "fn79" \h [79] HYPERLINK \l "fn80" \h [80] HYPERLINK \l "fn72" \h [72] HYPERLINK \l "fn78" \h [78]
Chlorophyllin and abscisic acid are still best treated as exploratory add-ons until more oral-cancer-specific data appear. HYPERLINK \l "fn82" \h [82] HYPERLINK \l "fn83" \h [83] HYPERLINK \l "fn81" \h [81]
Would you like me to turn this into a one-page formulation dossier with candidate doses, excipients, and a claim-safe label strategy for an oral-cancer-support product?
⁂

Find formulations where Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid act synergistically with other antioxidants/adaptogens; specify synergy rationale.Identify all formulations citing the same mechanism (Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling) as Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid in other botanical combinations for Oral Cancer.Search WHO ICTRP and CTRI for herbal clinical trials using Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid formulations for Oral Cancer; summarize arms and outcomes.List ethnobotanical or ancient records using Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling; connect to modern formulation analogs for Oral Cancer.Summarize gaps and limitations in existing public formulations of Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for Oral Cancer, identifying scope for innovation.
The public record shows a clear mechanistic pattern—antioxidant defense, cell-cycle arrest, pro-inflammatory suppression, and signaling modulation—but very few clinical formulations in oral cancer that combine chlorophyll/chlorophyllin, apigenin, quercetin/rutin, or abscisic acid with other botanicals/adaptogens in a way that is both explicit and standardized. The strongest documented synergies are quercetin-based nanoformulations, apigenin redox-modulating systems, chlorophyllin radioprotection trials, and flavonoid combinations that add antioxidants or bioenhancers rather than full adaptogen stacks. HYPERLINK \l "fn96" \h [96] HYPERLINK \l "fn97" \h [97] HYPERLINK \l "fn98" \h [98] HYPERLINK \l "fn99" \h [99] HYPERLINK \l "fn100" \h [100] HYPERLINK \l "fn101" \h [101] HYPERLINK \l "fn102" \h [102]
Synergistic pairings
Quercetin + piperine: the synergy rationale is bioavailability and transport inhibition; piperine inhibits P-gp/CYP pathways and helps quercetin reach higher exposure, while quercetin contributes antioxidant and anticancer activity. HYPERLINK \l "fn98" \h [98] HYPERLINK \l "fn100" \h [100] HYPERLINK \l "fn103" \h [103] HYPERLINK \l "fn104" \h [104] HYPERLINK \l "fn105" \h [105] HYPERLINK \l "fn106" \h [106]
Quercetin + resveratrol + genistein: a triple-SNEDDS improved oral bioavailability for all three antioxidants and showed enhanced antitumor activity in an in vivo cancer model, supporting the general idea that multiple polyphenols can cooperate through complementary redox and signaling effects. HYPERLINK \l "fn101" \h [101]
Quercetin + copper: the CTRI head-and-neck cancer trial used resveratrol with copper to reduce inflammatory cytokines via cell-free chromatin degradation; although not quercetin, it is a useful mechanistic analog for polyphenol-mineral synergy in cancer-related inflammation. HYPERLINK \l "fn107" \h [107]
Apigenin + cyclodextrin + nanoliposomes + in situ gel: synergy here is formulation-driven, not botanical-driven; cyclodextrin improves solubility, nanoliposomes protect the drug, and gel retention increases local exposure. HYPERLINK \l "fn108" \h [108] HYPERLINK \l "fn109" \h [109] HYPERLINK \l "fn110" \h [110]
Chlorophyllin + radiotherapy support: chlorophyllin is being evaluated as a radioprotective antioxidant in head-and-neck cancers, where the synergy is scavenging of free radicals and reduction of radiation injury rather than direct tumor killing. HYPERLINK \l "fn111" \h [111] HYPERLINK \l "fn112" \h [112] HYPERLINK \l "fn102" \h [102]
Same-mechanism formulations in other botanical combinations
Antioxidant: quercetin self-emulsifying systems, triple-antioxidant SNEDDS, and bioflavonol mixtures all use ROS scavenging as the main mechanism. HYPERLINK \l "fn100" \h [100] HYPERLINK \l "fn113" \h [113] HYPERLINK \l "fn114" \h [114] HYPERLINK \l "fn115" \h [115] HYPERLINK \l "fn116" \h [116] HYPERLINK \l "fn101" \h [101]
Cell-cycle arrest: apigenin and quercetin reviews repeatedly describe G0/G1 or G2/M arrest and downstream apoptosis as central anticancer mechanisms. HYPERLINK \l "fn97" \h [97] HYPERLINK \l "fn117" \h [117] HYPERLINK \l "fn99" \h [99] HYPERLINK \l "fn118" \h [118] HYPERLINK \l "fn119" \h [119] HYPERLINK \l "fn109" \h [109] HYPERLINK \l "fn110" \h [110]
Pro-inflammatory suppression: olive phenolic + flavonoid patents and piperine-enabled polyphenol systems are built around NF-κB, TNF-α, IL-6 and COX-linked inflammation control. HYPERLINK \l "fn105" \h [105] HYPERLINK \l "fn106" \h [106] HYPERLINK \l "fn120" \h [120] HYPERLINK \l "fn121" \h [121] HYPERLINK \l "fn122" \h [122]
Modulation of cell signaling: quercetin and rutin formulations repeatedly hit PI3K/Akt, MAPK, WNT/β-catenin and related nodes; apigenin also modulates ROS-linked signaling and autophagy/apoptosis. HYPERLINK \l "fn117" \h [117] HYPERLINK \l "fn99" \h [99] HYPERLINK \l "fn123" \h [123] HYPERLINK \l "fn124" \h [124] HYPERLINK \l "fn125" \h [125] HYPERLINK \l "fn126" \h [126] HYPERLINK \l "fn96" \h [96] HYPERLINK \l "fn98" \h [98]
WHO ICTRP and CTRI signals
I found a CTRI chlorophyllin trial in head-and-neck cancer supportive care, focused on radioprotection and toxicity reduction rather than direct oral-cancer tumor response. HYPERLINK \l "fn112" \h [112] HYPERLINK \l "fn102" \h [102] HYPERLINK \l "fn111" \h [111]
I found a CTRI head-and-neck resveratrol + copper trial with inflammatory cytokine endpoints and explicit dose arms, which is mechanistically similar to your polyphenol-plus-mineral question. HYPERLINK \l "fn107" \h [107]
I did not find a clear WHO ICTRP/CTRI trial in the retrieved records that combines chlorophyllin, apigenin, quercetin/rutin, or abscisic acid together for oral cancer endpoints; the portal records are mostly registry entry pages and broader head-and-neck studies. HYPERLINK \l "fn127" \h [127] HYPERLINK \l "fn128" \h [128] HYPERLINK \l "fn129" \h [129] HYPERLINK \l "fn130" \h [130]
The available trial outcomes are mainly mucositis, radioprotection, cytokines, tolerability, and quality of life, not tumor regression or biomarker-driven oral cancer response. HYPERLINK \l "fn131" \h [131] HYPERLINK \l "fn102" \h [102] HYPERLINK \l "fn107" \h [107]
Ethnobotanical and ancient parallels
Apigenin-rich plants such as parsley, chamomile, celery and citrus are repeatedly cited as medicinal herbs with antioxidant and anticancer relevance; modern formulations translate them into extracts, cyclodextrin complexes, liposomes or SNEDDS. HYPERLINK \l "fn109" \h [109] HYPERLINK \l "fn110" \h [110] HYPERLINK \l "fn117" \h [117]
Quercetin and rutin appear in onion, citrus, buckwheat and many traditional anti-inflammatory botanicals, and the bioflavonol patents essentially formalize a modern, standardized version of that long-standing ethnobotanical pattern. HYPERLINK \l "fn132" \h [132] HYPERLINK \l "fn113" \h [113] HYPERLINK \l "fn114" \h [114] HYPERLINK \l "fn115" \h [115] HYPERLINK \l "fn116" \h [116]
Chlorophyll-rich greens like wheatgrass and leafy vegetables are used historically for general “blood cleansing” or restorative purposes; modern analogs are chlorophyllin oral formulations and antioxidant mouth-support products. HYPERLINK \l "fn102" \h [102] HYPERLINK \l "fn133" \h [133]
Abscisic acid is the least represented in classic ethnobotany for oral cancer; its modern use is better viewed as an emerging signaling-active phytochemical rather than a traditional oral-cancer ingredient. HYPERLINK \l "fn134" \h [134]
Gaps and innovation scope
There is no strong public formulation ecosystem that unites chlorophyllin, apigenin, quercetin/rutin and abscisic acid into one oral-cancer-specific, clinically tested product. HYPERLINK \l "fn99" \h [99] HYPERLINK \l "fn96" \h [96] HYPERLINK \l "fn134" \h [134]
Evidence is fragmented across different indications: radioprotection, oral hygiene, general antioxidant support, and preclinical cancer models. HYPERLINK \l "fn111" \h [111] HYPERLINK \l "fn112" \h [112] HYPERLINK \l "fn102" \h [102]
Most human evidence targets supportive care or risk markers, not OSCC treatment outcomes, so the translational gap is delivery, dose standardization, and clinical endpoint selection. HYPERLINK \l "fn135" \h [135] HYPERLINK \l "fn131" \h [131] HYPERLINK \l "fn102" \h [102] HYPERLINK \l "fn107" \h [107]
A credible innovation path would combine: a) a flavonoid core (quercetin/apigenin/rutin), b) a bioenhancer or stabilizer (piperine, cyclodextrin, lipids), and c) a local delivery system for oral mucosa, while keeping claims in antioxidant and mucosal-support language. HYPERLINK \l "fn103" \h [103] HYPERLINK \l "fn104" \h [104] HYPERLINK \l "fn110" \h [110] HYPERLINK \l "fn100" \h [100] HYPERLINK \l "fn101" \h [101] HYPERLINK \l "fn108" \h [108] HYPERLINK \l "fn109" \h [109]
Best-supported design direction
For synergy, the best-supported pair is quercetin + piperine, followed by multi-polyphenol systems that add resveratrol or genistein. HYPERLINK \l "fn104" \h [104] HYPERLINK \l "fn136" \h [136] HYPERLINK \l "fn100" \h [100] HYPERLINK \l "fn101" \h [101]
For mechanism coverage, quercetin and apigenin are the best fit for antioxidant, cell-cycle arrest, and signaling modulation, while chlorophyllin is more useful for radioprotective/ROS-scavenging support. HYPERLINK \l "fn110" \h [110] HYPERLINK \l "fn97" \h [97] HYPERLINK \l "fn99" \h [99] HYPERLINK \l "fn102" \h [102] HYPERLINK \l "fn109" \h [109]
For innovation, the largest opening is a standardized oral strip/gel or lozenge with flavonoid-bioenhancer synergy and a small-molecule antioxidant stack, because that space is not yet crowded with direct oral-cancer formulations. HYPERLINK \l "fn100" \h [100] HYPERLINK \l "fn101" \h [101] HYPERLINK \l "fn104" \h [104] HYPERLINK \l "fn108" \h [108] HYPERLINK \l "fn134" \h [134]
Would you like a compact matrix of the best synergy pairs vs. delivery systems vs. oral-cancer mechanism?
⁂

Design a novel herbal formulation combining Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid with complementary botanicals to enhance Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling against Oral Cancer; justify synergy and ratios.Suggest bioenhancers or cofactors to improve bioavailability of Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid in Oral Cancer treatment; provide initial concentration ranges.Propose a nanoemulsion or liposomal delivery system to increase stability/solubility of Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling in Oral Cancer.Use network pharmacology to add synergistic herbs that strengthen Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid' mechanistic effects in Oral Cancer; list targets and pathways.Develop a sustained-release dosage form incorporating Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for prolonged Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling; outline polymer/excipient choices.
Below is a practical lead-design blueprint rather than a finished product claim, because public oral-cancer formulations that combine chlorophyllin, apigenin, quercetin/rutin, and abscisic acid in one standardized system are still sparse. The strongest evidence supports a flavonoid core, a bioenhancer, and a local oral delivery platform, with chlorophyllin best positioned as a supportive antioxidant/radioprotective co-agent rather than the main cytotoxic driver. HYPERLINK \l "fn146" \h [146] HYPERLINK \l "fn147" \h [147] HYPERLINK \l "fn148" \h [148] HYPERLINK \l "fn149" \h [149] HYPERLINK \l "fn150" \h [150] HYPERLINK \l "fn151" \h [151]
Proposed herbal core
Quercetin + rutin as the main anticancer/anti-inflammatory flavonoid axis, because nano-formulations show improved efficacy and molecular mechanisms across cancer models, and oral-cancer reviews link quercetin to apoptosis, cell-cycle arrest, metastasis suppression, and signaling modulation. HYPERLINK \l "fn152" \h [152] HYPERLINK \l "fn153" \h [153] HYPERLINK \l "fn148" \h [148] HYPERLINK \l "fn149" \h [149] HYPERLINK \l "fn146" \h [146]
Apigenin as the second flavonoid anchor, because oral-cancer models show redox modulation, apoptosis, and cell-cycle effects, and its solubility can be improved through cyclodextrin, liposomes, or nanoemulsion systems. HYPERLINK \l "fn151" \h [151] HYPERLINK \l "fn154" \h [154] HYPERLINK \l "fn155" \h [155] HYPERLINK \l "fn156" \h [156] HYPERLINK \l "fn157" \h [157]
Chlorophyllin as a local mucosal antioxidant and radioprotective adjunct, especially useful when oral mucosa is inflamed or exposed to radiation stress. HYPERLINK \l "fn158" \h [158] HYPERLINK \l "fn159" \h [159] HYPERLINK \l "fn160" \h [160]
Abscisic acid as an exploratory signaling modulator, but at a low level because oral-cancer-specific public evidence is thin; it fits best as a “novelty” component rather than a backbone ingredient. HYPERLINK \l "fn161" \h [161]
Synergy logic and ratios
A rational starting ratio for a prototype oral-cancer support blend would be: quercetin:rutin:apigenin:chlorophyllin:abscisic acid = 4:2:3:1:0.5 by actives mass, with the flavonoid fraction dominating. Quercetin and apigenin drive apoptosis, cell-cycle arrest and signaling suppression; rutin improves antioxidant coverage and may act as a more stable flavonol reservoir; chlorophyllin contributes ROS quenching; ABA is kept low to avoid overcomplicating interpretation while preserving a signaling signal. HYPERLINK \l "fn148" \h [148] HYPERLINK \l "fn149" \h [149] HYPERLINK \l "fn150" \h [150] HYPERLINK \l "fn146" \h [146] HYPERLINK \l "fn152" \h [152] HYPERLINK \l "fn151" \h [151]
Bioenhancers and cofactors
Piperine: strongest general bioenhancer for flavonoids; it inhibits efflux and metabolic clearance, and quercetin–piperine oral cancer data support the pairing. Suggested starting range: 2–10 mg per unit dose. HYPERLINK \l "fn162" \h [162] HYPERLINK \l "fn163" \h [163] HYPERLINK \l "fn164" \h [164] HYPERLINK \l "fn165" \h [165] HYPERLINK \l "fn166" \h [166] HYPERLINK \l "fn167" \h [167]
Cyclodextrin: best for apigenin and quercetin solubility/stability; suggested range in a formulation system is 1:1 to 1:4 drug:cylodextrin complexation. HYPERLINK \l "fn155" \h [155] HYPERLINK \l "fn156" \h [156] HYPERLINK \l "fn157" \h [157]
Vitamin C: co-antioxidant and stabilizer; suggested 25–100 mg per daily dose, mainly to reduce oxidative degradation and support mucosal antioxidant tone. HYPERLINK \l "fn168" \h [168] HYPERLINK \l "fn169" \h [169] HYPERLINK \l "fn170" \h [170]
Niacinamide and zinc: useful cofactors in DNA repair/oxidative resilience formulations; suggested niacinamide 50–250 mg and zinc 5–15 mg if a broader oral-mucosal-support positioning is intended. HYPERLINK \l "fn169" \h [169] HYPERLINK \l "fn170" \h [170] HYPERLINK \l "fn168" \h [168]
Phospholipids / lecithin: especially useful for chlorophyllin and lipophilic flavonoids in lipid vesicles or mixed micelles. HYPERLINK \l "fn147" \h [147] HYPERLINK \l "fn171" \h [171] HYPERLINK \l "fn150" \h [150]
Nanoemulsion / liposomal system
A strong first concept is a mixed liposomal-nanoemulsion hybrid:
Core phase: quercetin + apigenin in phospholipid bilayer or oil phase.
Aqueous shell: rutin, chlorophyllin, vitamin C, and low-dose ABA.
Stabilizers: soy lecithin, Tween/Polysorbate, PEGylated phospholipid, glycerol, and optional piperine in the oil phase.
Target particle size: about 80–180 nm for nanoemulsion and 100–220 nm for liposomes, with PDI ideally <0.3. HYPERLINK \l "fn171" \h [171] HYPERLINK \l "fn150" \h [150] HYPERLINK \l "fn163" \h [163] HYPERLINK \l "fn146" \h [146] HYPERLINK \l "fn147" \h [147]
This design is consistent with the oral-cancer nanotechnology literature showing that smaller particles improve mucosal deposition, solubility, and protection from metabolism. Quercetin nanoemulsions and nanoformulations have already shown improved anticancer performance and better oral epithelial dysplasia control in preclinical work. HYPERLINK \l "fn150" \h [150] HYPERLINK \l "fn146" \h [146] HYPERLINK \l "fn152" \h [152] HYPERLINK \l "fn171" \h [171]
Sustained-release oral dosage form
For prolonged oral exposure, the best direction is a mucoadhesive bilayer oral film or lozenge using:
Polymers: HPMC, pullulan, carbomer, chitosan, or sodium alginate.
Mucoadhesion enhancers: chitosan and carbomer are especially useful for oral retention.
Plasticizers: glycerol or sorbitol.
Release modifiers: ethyl cellulose or Eudragit RS/RL for sustained release, if a tablet/mini-tablet is preferred. HYPERLINK \l "fn172" \h [172] HYPERLINK \l "fn147" \h [147] HYPERLINK \l "fn171" \h [171]
A practical release pattern would be: fast release of piperine and vitamin C, intermediate release of quercetin/apigenin, and slower release of rutin/chlorophyllin/ABA. That gives an early bioavailability boost while sustaining antioxidant and pathway-modulating effects across several hours. HYPERLINK \l "fn146" \h [146] HYPERLINK \l "fn147" \h [147] HYPERLINK \l "fn150" \h [150] HYPERLINK \l "fn172" \h [172]
Mechanistic herb additions
Network-pharmacology-wise, the most defensible add-on herbs are green tea, parsley, chamomile, onion peel, and wheatgrass. Green tea adds EGCG for NF-κB, PI3K/Akt, and apoptosis signaling; parsley and chamomile reinforce apigenin; onion peel reinforces quercetin/rutin; wheatgrass contributes chlorophyll-rich antioxidant activity. HYPERLINK \l "fn154" \h [154] HYPERLINK \l "fn173" \h [173] HYPERLINK \l "fn174" \h [174] HYPERLINK \l "fn175" \h [175] HYPERLINK \l "fn176" \h [176] HYPERLINK \l "fn177" \h [177] HYPERLINK \l "fn161" \h [161]
Key targets and pathways to prioritize are:
Nrf2 / HO-1 / NQO1 for antioxidant defense.
NF-κB / COX-2 / IL-6 / TNF-α for pro-inflammatory suppression.
PI3K/Akt / MAPK / WNT-β-catenin / EGFR-Src for signaling control.
Cyclin D1 / CDK1 / p53 / Bax-Bcl-2 / caspases for cell-cycle arrest and apoptosis. HYPERLINK \l "fn149" \h [149] HYPERLINK \l "fn175" \h [175] HYPERLINK \l "fn177" \h [177] HYPERLINK \l "fn178" \h [178] HYPERLINK \l "fn179" \h [179] HYPERLINK \l "fn180" \h [180] HYPERLINK \l "fn148" \h [148] HYPERLINK \l "fn151" \h [151] HYPERLINK \l "fn154" \h [154]
Suggested starting concentration ranges
For an experimental oral-cancer support prototype, a reasonable per daily unit starting window is:
Quercetin: 100–300 mg.
Rutin: 50–200 mg.
Apigenin: 25–100 mg.
Chlorophyllin: 20–100 mg.
Abscisic acid: 0.5–10 mg.
Piperine: 2–10 mg.
Vitamin C: 25–100 mg.
Zinc: 5–15 mg.
Niacinamide: 50–250 mg. HYPERLINK \l "fn163" \h [163] HYPERLINK \l "fn170" \h [170] HYPERLINK \l "fn150" \h [150] HYPERLINK \l "fn162" \h [162] HYPERLINK \l "fn168" \h [168] HYPERLINK \l "fn169" \h [169] HYPERLINK \l "fn146" \h [146]
Innovation gaps
The main gaps are: no standardized oral-cancer product combining all five phytochemical classes; limited human data beyond quercetin and chlorophyllin supportive-care settings; weak evidence for abscisic acid in oral cancer; and insufficient head-to-head comparison of local oral delivery systems. The biggest innovation opportunity is a mucoadhesive nano-enabled oral film or lozenge that uses a flavonoid backbone plus chlorophyllin and a bioenhancer, while keeping claims in antioxidant/oral-mucosal-support language. HYPERLINK \l "fn159" \h [159] HYPERLINK \l "fn160" \h [160] HYPERLINK \l "fn147" \h [147] HYPERLINK \l "fn152" \h [152] HYPERLINK \l "fn150" \h [150] HYPERLINK \l "fn158" \h [158] HYPERLINK \l "fn146" \h [146]
If you want, I can turn this into a single formulation specification sheet with exact excipients, layer architecture, and a candidate claim set for an oral strip, lozenge, or mouthwash.
⁂

Formulate a polyherbal blend combining Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid with adaptogens for Oral Cancer management; include titration strategy.Design a novel dosage form (transdermal patch, buccal film, oral strip) for Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid targeting Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling in Oral Cancer.Suggest optimal excipients and antioxidants for stabilizing Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid extract during formulation development; include pH and solvent windows.Recommend synergistic combinations of Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid with amino acids/peptides/vitamins to enhance Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling; propose ratios.Create a formulation concept integrating Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid with prebiotics or microbiome modulators for Oral Cancer; outline capsule vs. sachet options.
A plausible novel design is a mucoadhesive buccal film/oral strip built around quercetin–rutin–apigenin as the main anticancer flavonoid triad, with chlorophyllin for redox buffering and a very low-dose ABA “signal modulator” layer; adaptogens should be chosen to reinforce inflammation control and stress resilience rather than to dominate the pharmacology. The most evidence-aligned adaptogen add-ons are ashwagandha, holy basil, and astragalus, because they support anti-inflammatory, antioxidant, and immune-modulatory biology that complements flavonoid-driven apoptosis and cell-cycle arrest. HYPERLINK \l "fn187" \h [187] HYPERLINK \l "fn188" \h [188] HYPERLINK \l "fn189" \h [189] HYPERLINK \l "fn190" \h [190] HYPERLINK \l "fn191" \h [191] HYPERLINK \l "fn192" \h [192]
Polyherbal blend
Backbone actives: quercetin 200 mg, rutin 100 mg, apigenin 50 mg, chlorophyllin 25 mg, ABA 2 mg per daily dose unit. These levels keep quercetin dominant, give rutin as a stabilizing/slow-release flavonol reservoir, place apigenin in a meaningful but manufacturable range, and keep ABA exploratory. HYPERLINK \l "fn193" \h [193] HYPERLINK \l "fn188" \h [188] HYPERLINK \l "fn189" \h [189] HYPERLINK \l "fn194" \h [194] HYPERLINK \l "fn190" \h [190] HYPERLINK \l "fn192" \h [192] HYPERLINK \l "fn187" \h [187]
Adaptogens: ashwagandha extract 100–200 mg, holy basil extract 50–100 mg, astragalus extract 100 mg, optionally Rhodiola 25–50 mg if a non-sedating profile is desired. The synergy rationale is broad stress-response buffering plus immunomodulation that may improve tolerance and inflammatory tone during oral mucosal exposure. HYPERLINK \l "fn190" \h [190] HYPERLINK \l "fn191" \h [191]
Titration strategy: start at one-third dose for 3–5 days, increase to two-thirds dose for the next 5–7 days, then full dose if local mucosal irritation is absent. This is the safest way to introduce chlorophyllin and flavonoids into a contact-dose oral system, especially when adaptogens are added. HYPERLINK \l "fn189" \h [189] HYPERLINK \l "fn192" \h [192] HYPERLINK \l "fn187" \h [187] HYPERLINK \l "fn190" \h [190]
Dosage form
Best option: buccal film / oral strip rather than transdermal patch. The oral mucosa offers direct contact with the target tissue, while transdermal delivery is poorly suited for these polar polyphenols and cannot easily achieve local oral-cavity exposure. HYPERLINK \l "fn195" \h [195] HYPERLINK \l "fn196" \h [196] HYPERLINK \l "fn197" \h [197]
Secondary option: a slow-dissolve lozenge if film loading becomes too high or taste masking is difficult. Lozenges offer longer residence time, simpler manufacture, and better flavor control. HYPERLINK \l "fn197" \h [197] HYPERLINK \l "fn195" \h [195]
Not preferred: transdermal patch, because the molecular mix is too hydrophilic/complex and the disease target is local oral mucosa, not systemic skin delivery. HYPERLINK \l "fn196" \h [196] HYPERLINK \l "fn195" \h [195]
Excipients and stability
Film polymers: HPMC + pullulan or HPMC + chitosan for mucoadhesion and controlled release.
Plasticizers: glycerol or sorbitol at low-to-moderate levels.
Stabilizers: ascorbyl palmitate, tocopherol, citric acid, and phospholipid/lecithin for oxidation control.
Solvent window: hydroalcoholic processing is preferred; keep ethanol low enough for film casting but high enough for flavonoid solubilization, with final product pH around 5.5–6.5 to protect chlorophyllin and preserve oral comfort. HYPERLINK \l "fn198" \h [198] HYPERLINK \l "fn199" \h [199] HYPERLINK \l "fn200" \h [200] HYPERLINK \l "fn201" \h [201] HYPERLINK \l "fn202" \h [202] HYPERLINK \l "fn197" \h [197]
Bioenhancers and cofactors
Piperine 2–5 mg can be added if systemic exposure is desired, but in a buccal film it should be used conservatively because it may irritate mucosa and overly alter metabolism. HYPERLINK \l "fn203" \h [203] HYPERLINK \l "fn204" \h [204] HYPERLINK \l "fn205" \h [205] HYPERLINK \l "fn206" \h [206] HYPERLINK \l "fn207" \h [207]
Cyclodextrin is a better first-line solubilizer for apigenin and quercetin in oral strips.
Vitamin C 25–100 mg is a useful co-antioxidant and color/protection aid.
Niacinamide 50–100 mg and zinc 5–10 mg are optional cofactors if you want a DNA-repair/oxidative-resilience positioning.
L-glutamine 100–250 mg can be considered for mucosal support, especially if irritation is a concern. HYPERLINK \l "fn199" \h [199] HYPERLINK \l "fn200" \h [200] HYPERLINK \l "fn202" \h [202] HYPERLINK \l "fn208" \h [208] HYPERLINK \l "fn209" \h [209] HYPERLINK \l "fn210" \h [210] HYPERLINK \l "fn198" \h [198]
Nano-delivery concept
A strong option is a liposomal nanoemulsion-in-film hybrid: quercetin and apigenin in the lipid phase, rutin and chlorophyllin in the aqueous phase, ABA at trace level in the internal aqueous compartment, and adaptogen extracts in a separate standardized fraction to avoid instability. Target particle size should be 80–180 nm, with PDI under 0.3 and physically stable dispersion over refrigerated storage. HYPERLINK \l "fn202" \h [202] HYPERLINK \l "fn204" \h [204] HYPERLINK \l "fn211" \h [211] HYPERLINK \l "fn195" \h [195] HYPERLINK \l "fn197" \h [197]
Network pharmacology add-ons
Ashwagandha: withanolides may reinforce NF-κB suppression, apoptosis, and stress-adaptation pathways.
Holy basil: eugenol/ursolic-acid-rich extracts support anti-inflammatory and antioxidant signaling.
Astragalus: polysaccharides and saponins can support immune modulation and redox resilience.
Green tea / EGCG can be added in low dose if a stronger PI3K/Akt, MAPK, and apoptosis signature is wanted.These additions strengthen the same network already implicated for quercetin and apigenin: Nrf2, NF-κB, PI3K/Akt, MAPK, WNT/β-catenin, EGFR-Src, cyclins/CDKs, Bax/Bcl-2, and caspases. HYPERLINK \l "fn188" \h [188] HYPERLINK \l "fn194" \h [194] HYPERLINK \l "fn191" \h [191] HYPERLINK \l "fn187" \h [187] HYPERLINK \l "fn193" \h [193] HYPERLINK \l "fn190" \h [190]
Prebiotic or microbiome option
A capsule or sachet version can pair the botanical blend with galactomannan, inulin, or resistant dextrin as a microbiome-support layer, especially because quercetin’s bioactivity is partly shaped by gut microbial metabolism. This is better suited to a capsule/sachet than a film, while the film remains the preferred local oral-cavity dosage form. HYPERLINK \l "fn212" \h [212] HYPERLINK \l "fn213" \h [213]
Capsule vs sachet
Capsule: better for standardized systemic support, easier to include prebiotics and adaptogens, but weaker local oral exposure.
Sachet: better for powder blends, prebiotics, and flexible dosing, but taste masking becomes harder.
Buccal film: best for direct oral-cavity targeting, sustained residence, and lower total dose. HYPERLINK \l "fn214" \h [214] HYPERLINK \l "fn195" \h [195] HYPERLINK \l "fn196" \h [196] HYPERLINK \l "fn197" \h [197]
Practical ratio framework
A workable starting formulation ratio for a film could be:
Quercetin:rutin:apigenin:chlorophyllin:ABA = 40:20:10:5:1
Adaptogens total = 1 to 2 parts of the flavonoid base, split across 2–3 botanicals
Bioenhancer/cofactor bundle = 5 to 10 parts of the active core massThis preserves the flavonoids as the main active engine and keeps adaptogens supportive. HYPERLINK \l "fn191" \h [191] HYPERLINK \l "fn192" \h [192] HYPERLINK \l "fn187" \h [187] HYPERLINK \l "fn188" \h [188] HYPERLINK \l "fn189" \h [189] HYPERLINK \l "fn190" \h [190]
Innovation scope
The most novel part of this concept is not the individual ingredients but their local oral delivery + standardized release + microbiome/adaptogen support in one system. The biggest technical risks are chlorophyllin discoloration, apigenin/quercetin poor solubility, taste masking, and keeping ABA meaningful without overcomplicating the claim package. HYPERLINK \l "fn195" \h [195] HYPERLINK \l "fn197" \h [197] HYPERLINK \l "fn202" \h [202]
Would you like me to turn this into a prototype composition table with exact mg per strip, film thickness, release profile, and manufacturing steps?
⁂

Draft a multi-target formulation by combining Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid with pathway-specific herbs; map mechanism to Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling in Oral Cancer.Propose an evidence-based formulation that reduces side effects of conventional drugs for Oral Cancer when co-administered with Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid.Design a topical formulation (cream/serum/gel) using Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for localized Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling; include permeation enhancers and viscosity range.Encapsulate Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid in biodegradable polymer microspheres for targeted delivery; specify particle size targets and release profile.Write a patent-ready abstract for a novel Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid-based formulation targeting Oral Cancer via Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling; include novelty and inventive step.
A credible patent-style formulation concept is a mucoadhesive oral gel or buccal film built around quercetin–rutin–apigenin as the primary anticancer triad, chlorophyllin as an antioxidant/radioprotective cofactor, and ABA as a low-dose signaling adjunct. To improve tolerability with conventional oral-cancer drugs, the same platform can be positioned as an adjuvant to cisplatin or radiotherapy because quercetin has published evidence for reducing cisplatin toxicity while preserving anticancer activity. HYPERLINK \l "fn220" \h [220] HYPERLINK \l "fn221" \h [221] HYPERLINK \l "fn222" \h [222] HYPERLINK \l "fn223" \h [223] HYPERLINK \l "fn224" \h [224]
Multi-target herbal map
Quercetin: apoptosis, cell-cycle arrest, metastasis suppression, chemosensitization, and protection against cisplatin adverse effects. HYPERLINK \l "fn221" \h [221] HYPERLINK \l "fn222" \h [222] HYPERLINK \l "fn224" \h [224] HYPERLINK \l "fn220" \h [220]
Apigenin: antioxidant and cell-cycle modulator; useful for ROS-linked cytotoxicity in oral cancer cells. HYPERLINK \l "fn225" \h [225] HYPERLINK \l "fn226" \h [226] HYPERLINK \l "fn227" \h [227]
Rutin: antioxidant reservoir and signaling modulator; supports quercetin-like flavonol biology with better handling in formulation. HYPERLINK \l "fn228" \h [228] HYPERLINK \l "fn229" \h [229] HYPERLINK \l "fn230" \h [230]
Chlorophyllin: ROS buffering and mucosal protection, especially useful in radiation-associated oral injury. HYPERLINK \l "fn231" \h [231] HYPERLINK \l "fn232" \h [232] HYPERLINK \l "fn233" \h [233]
ABA: low-dose exploratory signaling support; use as an adjunct, not the main effect driver. HYPERLINK \l "fn234" \h [234]
Pathway-specific herbs
A synergistic herbal set for oral cancer would be:
Green tea (EGCG) for NF-κB, PI3K/Akt and apoptosis support.
Parsley/chamomile as apigenin sources for cell-cycle arrest and oxidative balance.
Onion peel/citrus as quercetin/rutin sources for anti-inflammatory and anti-metastatic activity.
Wheatgrass for chlorophyll-rich antioxidant support.
Tulsi / ashwagandha / astragalus as adaptogens to reduce inflammatory stress and support treatment tolerance. HYPERLINK \l "fn226" \h [226] HYPERLINK \l "fn227" \h [227] HYPERLINK \l "fn235" \h [235] HYPERLINK \l "fn236" \h [236] HYPERLINK \l "fn237" \h [237] HYPERLINK \l "fn238" \h [238] HYPERLINK \l "fn239" \h [239]
Evidence-based adjuvant concept
For co-administration with conventional therapy, the strongest evidence-backed use case is quercetin as a cisplatin adjunct. Published reviews report that quercetin can enhance anticancer efficacy and reduce cisplatin adverse effects such as nephrotoxicity and ototoxicity, while observational head-and-neck data suggest quercetin-rich diets improved treatment tolerance and reduced weight loss. HYPERLINK \l "fn222" \h [222] HYPERLINK \l "fn223" \h [223] HYPERLINK \l "fn240" \h [240] HYPERLINK \l "fn224" \h [224] HYPERLINK \l "fn220" \h [220]
A practical adjuvant blend would therefore center on quercetin plus rutin and chlorophyllin, with apigenin as a secondary antiproliferative agent and adaptogens added mainly to reduce inflammation and mucositis burden. HYPERLINK \l "fn227" \h [227] HYPERLINK \l "fn238" \h [238] HYPERLINK \l "fn239" \h [239] HYPERLINK \l "fn241" \h [241] HYPERLINK \l "fn220" \h [220] HYPERLINK \l "fn221" \h [221] HYPERLINK \l "fn226" \h [226]
Topical gel design
A topical oral gel is the best fit for localized exposure, especially for premalignant lesions or mucosal fields. A reasonable starting viscosity range is roughly 10,000–50,000 cP for a mucoadhesive gel, with the upper end preferred for oral retention and the lower end for spreadability. HYPERLINK \l "fn242" \h [242] HYPERLINK \l "fn243" \h [243] HYPERLINK \l "fn244" \h [244]
Suggested components:
Mucoadhesive base: carbomer, HPMC, chitosan, or sodium alginate.
Permeation enhancers: piperine low-dose, phospholipids, lecithin, and mild surfactants such as polysorbate 80.
Protectants/stabilizers: ascorbic acid, tocopherol, citric acid, sodium metabisulfite only if justified and acceptable, and light-protective packaging.
pH window: approximately 5.5–6.5. This is gentle for oral tissue and compatible with chlorophyllin stability and flavonoid handling. HYPERLINK \l "fn244" \h [244] HYPERLINK \l "fn245" \h [245] HYPERLINK \l "fn246" \h [246] HYPERLINK \l "fn247" \h [247] HYPERLINK \l "fn248" \h [248] HYPERLINK \l "fn228" \h [228]
Microspheres
For targeted delivery, biodegradable microspheres can be built from PLGA, chitosan, alginate, or polycaprolactone. A good particle-size target is 1–10 µm for oral mucosal retention, or 200–800 nm if you want nano-microsphere hybrids; larger microspheres favor local deposition, while submicron systems improve uptake and release control. HYPERLINK \l "fn243" \h [243] HYPERLINK \l "fn249" \h [249] HYPERLINK \l "fn228" \h [228] HYPERLINK \l "fn242" \h [242] HYPERLINK \l "fn244" \h [244]
A sensible release profile is:
Initial burst of 10–20% over 1–2 hours for quercetin/apigenin.
Sustained release over 8–24 hours for rutin/chlorophyllin.
Very slow trace release for ABA and adaptogen fractions if included. HYPERLINK \l "fn228" \h [228] HYPERLINK \l "fn242" \h [242] HYPERLINK \l "fn244" \h [244]
Patent-ready abstract
Abstract:A novel mucoadhesive oral formulation is disclosed for adjunct management of oral cancer and oral premalignant lesions, comprising standardized extracts and/or purified fractions of quercetin, rutin, apigenin, chlorophyllin, and abscisic acid, optionally combined with pathway-specific botanicals selected from green tea, parsley, chamomile, onion peel, wheatgrass, ashwagandha, tulsi, and astragalus. The formulation is designed as a topical gel, buccal film, oral strip, or biodegradable microsphere system to provide sustained mucosal exposure. The composition is further characterized by one or more bioenhancers, permeability modifiers, and stabilizers that increase solubility, mucosal residence, and local bioavailability of the active phytochemicals. The formulation acts through a multi-target mechanism involving antioxidant defense, modulation of redox stress, induction of cell-cycle arrest, suppression of pro-inflammatory signaling, and regulation of oncogenic pathways including NF-κB, PI3K/Akt, MAPK, WNT/β-catenin, and apoptosis-related cascades. The inventive step resides in the combined use of a flavonoid-rich core with chlorophyllin and low-dose abscisic acid in a localized oral delivery platform, optionally co-administered with conventional chemotherapy to enhance efficacy and reduce treatment-related toxicity. HYPERLINK \l "fn224" \h [224] HYPERLINK \l "fn229" \h [229] HYPERLINK \l "fn241" \h [241] HYPERLINK \l "fn220" \h [220] HYPERLINK \l "fn221" \h [221] HYPERLINK \l "fn222" \h [222] HYPERLINK \l "fn226" \h [226] HYPERLINK \l "fn244" \h [244] HYPERLINK \l "fn228" \h [228]
Practical ratios
A defensible starting ratio for development work is:
Quercetin:rutin:apigenin:chlorophyllin:ABA = 40:20:10:5:1
Add adaptogens at 10–25% of the flavonoid mass
Keep piperine at 2–5% of total active mass if used
Keep vitamins/minerals as adjuncts rather than dominant actives, especially if the aim is local oral delivery. HYPERLINK \l "fn245" \h [245] HYPERLINK \l "fn246" \h [246] HYPERLINK \l "fn247" \h [247] HYPERLINK \l "fn249" \h [249] HYPERLINK \l "fn250" \h [250] HYPERLINK \l "fn244" \h [244] HYPERLINK \l "fn228" \h [228]
Innovation scope
The most novel element is not the ingredients themselves, but the combination of a flavonoid/chlorophyllin core with an oral-retentive delivery system and an adjuvant-to-chemotherapy positioning. The biggest limitations are chlorophyllin stability, taste masking, and the lack of human oral-cancer trials for the full combination, which makes preclinical validation essential. HYPERLINK \l "fn232" \h [232] HYPERLINK \l "fn233" \h [233] HYPERLINK \l "fn220" \h [220] HYPERLINK \l "fn221" \h [221] HYPERLINK \l "fn231" \h [231] HYPERLINK \l "fn244" \h [244]
Would you like me to convert this into a claim chart plus formulation table with exact excipients, process steps, and test endpoints?
⁂

Use AI-based ingredient ranking to select top synergistic compounds with Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling; output top-10 with rationale.Propose a multi-dose comparative study to optimize concentration ratios in a Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid-based formulation; define endpoints for Oral Cancer.Develop a concept pairing Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid with FDA-compliant nutraceuticals to enhance safety/efficacy; list regulatory category options.Suggest optimization parameters (pH, solvent, stabilizer, antioxidant) for high-potency Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid extracts aimed at Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling.Design a green extraction + formulation workflow for sustainable production of Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid formulation; include QC checkpoints.
Here is a development-oriented shortlist and optimization plan grounded in the oral-cancer literature, with quercetin and chlorophyllin carrying the strongest direct evidence and apigenin/nano-delivery providing the strongest formulation leverage. HYPERLINK \l "fn259" \h [259] HYPERLINK \l "fn260" \h [260] HYPERLINK \l "fn261" \h [261] HYPERLINK \l "fn262" \h [262]
Top synergistic add-ons
Piperine — strongest bioenhancer for quercetin/apigenin; improves absorption and makes low-dose flavonoids more pharmacologically reachable. HYPERLINK \l "fn260" \h [260] HYPERLINK \l "fn263" \h [263] HYPERLINK \l "fn264" \h [264]
Resveratrol — adds NF-κB, PI3K/Akt, apoptosis, and chemosensitization support, with good synergy potential alongside quercetin. HYPERLINK \l "fn261" \h [261] HYPERLINK \l "fn265" \h [265]
EGCG — reinforces antioxidant defense and anti-proliferative signaling through multiple cancer pathways. HYPERLINK \l "fn266" \h [266] HYPERLINK \l "fn267" \h [267]
Genistein — complements quercetin/apigenin on tyrosine-kinase and epigenetic signaling. HYPERLINK \l "fn265" \h [265] HYPERLINK \l "fn267" \h [267]
Withaferin A / ashwagandha withanolides — useful for inflammatory stress and apoptosis modulation. HYPERLINK \l "fn268" \h [268] HYPERLINK \l "fn269" \h [269]
Curcumin — broad anti-inflammatory and pathway-modulating activity, especially useful in a multiplex botanical blend. HYPERLINK \l "fn270" \h [270] HYPERLINK \l "fn271" \h [271]
Luteolin — flavone sibling of apigenin with overlapping cell-cycle and inflammatory effects. HYPERLINK \l "fn267" \h [267] HYPERLINK \l "fn272" \h [272]
Sulforaphane — strong Nrf2 activation and chemopreventive logic for mucosal tissues. HYPERLINK \l "fn273" \h [273]
Vitamin C — supports redox balance and may help stabilize phenolics in formulation. HYPERLINK \l "fn274" \h [274] HYPERLINK \l "fn275" \h [275] HYPERLINK \l "fn276" \h [276]
Zinc / niacinamide — useful cofactors for DNA repair and mucosal resilience. HYPERLINK \l "fn275" \h [275] HYPERLINK \l "fn276" \h [276] HYPERLINK \l "fn274" \h [274]
Comparative dose study
A multi-arm study should compare fixed-flavonoid ratios with and without bioenhancers to identify the best balance of efficacy and tolerability. HYPERLINK \l "fn259" \h [259] HYPERLINK \l "fn260" \h [260] HYPERLINK \l "fn261" \h [261]
Arm A: quercetin:rutin:apigenin:chlorophyllin:ABA = 40:20:10:5:1. HYPERLINK \l "fn277" \h [277] HYPERLINK \l "fn261" \h [261] HYPERLINK \l "fn259" \h [259]
Arm B: same core plus piperine 1–2% w/w. HYPERLINK \l "fn264" \h [264] HYPERLINK \l "fn260" \h [260]
Arm C: same core plus resveratrol 10–20% of flavonoid mass. HYPERLINK \l "fn261" \h [261] HYPERLINK \l "fn265" \h [265]
Arm D: same core plus EGCG 10–15% of flavonoid mass. HYPERLINK \l "fn266" \h [266] HYPERLINK \l "fn267" \h [267]
Arm E: same core plus sulforaphane-rich fraction and vitamin C. HYPERLINK \l "fn276" \h [276] HYPERLINK \l "fn273" \h [273] HYPERLINK \l "fn274" \h [274] HYPERLINK \l "fn275" \h [275]
Oral-cancer endpoints
Primary endpoints should be lesion regression, proliferation index, apoptosis markers, and tolerability. Secondary endpoints should include NF-κB, Nrf2, PI3K/Akt, COX-2, MMP-9, cyclin D1, cleaved caspase-3, and oxidative-stress biomarkers. HYPERLINK \l "fn278" \h [278] HYPERLINK \l "fn279" \h [279] HYPERLINK \l "fn260" \h [260] HYPERLINK \l "fn259" \h [259] HYPERLINK \l "fn261" \h [261]
FDA-compliant nutraceutical pairing
For a compliant nutraceutical concept, pair the botanicals with vitamin C, zinc, niacinamide, and phospholipid-based delivery because these are familiar dietary ingredients with lower regulatory friction than drug-like claims. HYPERLINK \l "fn263" \h [263] HYPERLINK \l "fn260" \h [260] HYPERLINK \l "fn274" \h [274] HYPERLINK \l "fn275" \h [275] HYPERLINK \l "fn276" \h [276]Potential regulatory categories include:
Dietary supplement.
Medical food.
Botanical drug development candidate.
Oral care/nutricosmetic adjunct if positioned for mucosal wellness rather than cancer treatment. HYPERLINK \l "fn274" \h [274] HYPERLINK \l "fn275" \h [275] HYPERLINK \l "fn276" \h [276]
Optimization parameters
pH: 5.5–6.5 for oral-contact systems. HYPERLINK \l "fn280" \h [280] HYPERLINK \l "fn270" \h [270]
Solvent: hydroalcoholic or ethanol-assisted processing for flavonoid extraction, with final product solvent minimized. HYPERLINK \l "fn281" \h [281] HYPERLINK \l "fn270" \h [270]
Stabilizer: lecithin, cyclodextrin, or PEGylated phospholipid for solubility; HPMC or chitosan for matrix stability. HYPERLINK \l "fn282" \h [282] HYPERLINK \l "fn260" \h [260] HYPERLINK \l "fn280" \h [280] HYPERLINK \l "fn281" \h [281]
Antioxidant: ascorbic acid, tocopherol, citric acid. HYPERLINK \l "fn275" \h [275] HYPERLINK \l "fn276" \h [276] HYPERLINK \l "fn274" \h [274]
Green extraction workflow
Raw material selection: parsley/chamomile for apigenin; onion peel/citrus for quercetin; wheatgrass for chlorophyll; standardized ABA source. HYPERLINK \l "fn272" \h [272] HYPERLINK \l "fn283" \h [283] HYPERLINK \l "fn284" \h [284] HYPERLINK \l "fn259" \h [259]
Green extraction: ethanol-water, deep eutectic solvent, or supercritical CO₂ depending on target polarity. HYPERLINK \l "fn285" \h [285] HYPERLINK \l "fn270" \h [270]
Standardization: HPLC for quercetin/apigenin/rutin, UV-Vis or HPLC for chlorophyllin, LC-MS for ABA. HYPERLINK \l "fn286" \h [286] HYPERLINK \l "fn287" \h [287] HYPERLINK \l "fn281" \h [281]
Formulation: nanoliposomes, nanoemulsion, or mucoadhesive film. HYPERLINK \l "fn288" \h [288] HYPERLINK \l "fn260" \h [260] HYPERLINK \l "fn280" \h [280] HYPERLINK \l "fn282" \h [282]
QC: assay content, residual solvent, particle size, PDI, zeta potential, moisture, microbial load, and accelerated stability. HYPERLINK \l "fn260" \h [260] HYPERLINK \l "fn286" \h [286] HYPERLINK \l "fn281" \h [281]
Best first development path
The most evidence-backed route is quercetin + piperine + rutin + apigenin as the core, chlorophyllin as a mucosal antioxidant add-on, and vitamins/minerals as safety cofactors. That gives the best chance of hitting antioxidant, cell-cycle arrest, inflammatory suppression, and signaling modulation while staying realistic for oral-cancer adjunct development. HYPERLINK \l "fn263" \h [263] HYPERLINK \l "fn276" \h [276] HYPERLINK \l "fn259" \h [259] HYPERLINK \l "fn260" \h [260] HYPERLINK \l "fn261" \h [261] HYPERLINK \l "fn274" \h [274] HYPERLINK \l "fn275" \h [275]
Would you like a study matrix with four formulations, exact mg/ratio targets, and endpoint readouts next?
⁂

Propose a personalized formulation strategy using Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for Oral Cancer integrating biomarkers/genetics; define stratification rules.Create a prevention + therapy dual-use formulation with Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid for Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling; define low vs. high-dose SKUs.Generate a hypothesis for synergy between Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid and standard of care drugs for Oral Cancer; propose interaction mitigations.Outline a bench-to-clinic pipeline for a Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid-based formulation (in-silico → in-vitro → pilot clinical) focusing on Antioxidant, Cell-cycle arrest, Pro-inflammatory, Modulation of cell signaling.Draft a product dossier summary describing a novel Chorophyll/Chlorophyllin/Apigenin/Flavonoids,Rutin/Quercetin,Abscisic acid-based formulation with differentiation, safety, and potential IP claims.
Below is a decision framework you can use to personalize and advance the formulation while keeping it anchored to oral-cancer biology. The strongest human-relevant stratification signals in the retrieved evidence are oxidative stress, cisplatin sensitivity/toxicity, invasion/metastasis markers, and miRNA/AKT/WNT-related signaling changes. HYPERLINK \l "fn295" \h [295] HYPERLINK \l "fn296" \h [296] HYPERLINK \l "fn297" \h [297] HYPERLINK \l "fn298" \h [298] HYPERLINK \l "fn299" \h [299]
Stratification rules
Oxidative-stress dominant phenotype: prioritize quercetin, rutin, chlorophyllin, and vitamin C when ROS, lipid peroxidation, or inflammatory biomarkers are high. Quercetin’s oral-cancer evidence repeatedly centers on oxidative damage, apoptosis, and anti-metastasis effects. HYPERLINK \l "fn300" \h [300] HYPERLINK \l "fn301" \h [301] HYPERLINK \l "fn295" \h [295]
Proliferative / cell-cycle dominant phenotype: prioritize apigenin plus quercetin, with EGCG or genistein as signaling partners, when Cyclin D1, Ki-67, p-AKT, or WNT/β-catenin markers are elevated. HYPERLINK \l "fn297" \h [297] HYPERLINK \l "fn299" \h [299] HYPERLINK \l "fn302" \h [302] HYPERLINK \l "fn303" \h [303] HYPERLINK \l "fn304" \h [304]
Chemo-sensitization phenotype: prioritize quercetin + piperine + chlorophyllin when the patient is receiving cisplatin or radiotherapy and there is concern for resistance or toxicity. Quercetin has published evidence for cisplatin sensitization and protective effects against some side effects. HYPERLINK \l "fn296" \h [296] HYPERLINK \l "fn305" \h [305] HYPERLINK \l "fn306" \h [306] HYPERLINK \l "fn295" \h [295]
Inflammatory / mucositis-prone phenotype: add chlorophyllin and adaptogenic anti-inflammatory herbs such as holy basil or ashwagandha to support mucosal tolerance and inflammatory tone. HYPERLINK \l "fn307" \h [307] HYPERLINK \l "fn308" \h [308] HYPERLINK \l "fn309" \h [309] HYPERLINK \l "fn310" \h [310] HYPERLINK \l "fn311" \h [311]
Metastatic / invasion-prone phenotype: weight quercetin and rutin higher, because oral-cancer studies show suppression of migration, invasion, MMP-2/MMP-9 and miR-16/HOXA10 or miR-1254/CD36 signaling. HYPERLINK \l "fn298" \h [298] HYPERLINK \l "fn299" \h [299] HYPERLINK \l "fn297" \h [297]
Personalized formulation strategy
A practical personalized core is: quercetin 40%, rutin 20%, apigenin 15%, chlorophyllin 10%, ABA 5%, and the remaining 10% split between bioenhancers/cofactors. In higher-risk or treatment-adjunct patients, shift the balance toward quercetin and piperine; in mucositis-prone patients, shift toward chlorophyllin, vitamin C, and mucosal protectants. HYPERLINK \l "fn312" \h [312] HYPERLINK \l "fn313" \h [313] HYPERLINK \l "fn295" \h [295] HYPERLINK \l "fn296" \h [296] HYPERLINK \l "fn307" \h [307]
Prevention + therapy dual use
Low-dose SKU: for prevention or field cancerization, use lower flavonoid loading, more chlorophyllin, and fewer bioenhancers to improve tolerability. HYPERLINK \l "fn300" \h [300] HYPERLINK \l "fn307" \h [307]
High-dose SKU: for adjunct therapy, increase quercetin/apigenin loading and include piperine or lipid carriers to improve exposure. HYPERLINK \l "fn314" \h [314] HYPERLINK \l "fn313" \h [313] HYPERLINK \l "fn315" \h [315] HYPERLINK \l "fn316" \h [316]This dual-SKU strategy lets the same platform serve both premalignant lesions and active oral-cancer support. HYPERLINK \l "fn295" \h [295] HYPERLINK \l "fn312" \h [312] HYPERLINK \l "fn300" \h [300]
Synergy with standard of care
A reasonable synergy hypothesis is that this formulation would increase tumor-cell ROS stress and apoptosis while reducing inflammatory escape and resistance signaling, thereby improving the effect of cisplatin or radiotherapy and reducing mucosal injury. Quercetin is the anchor for this hypothesis because it has evidence for sensitizing OSCC to cisplatin and modulating cholesterol/AKT-related resistance pathways. HYPERLINK \l "fn305" \h [305] HYPERLINK \l "fn306" \h [306] HYPERLINK \l "fn296" \h [296] HYPERLINK \l "fn295" \h [295]Mitigations:
Use staggered dosing so the botanical dose is not taken simultaneously with peak chemotherapy exposure.
Prefer localized buccal delivery for oral-field effect rather than high systemic piperine exposure.
Monitor drug–herb interactions if patients take CYP-sensitive drugs. HYPERLINK \l "fn313" \h [313] HYPERLINK \l "fn315" \h [315] HYPERLINK \l "fn317" \h [317] HYPERLINK \l "fn318" \h [318] HYPERLINK \l "fn296" \h [296]
Bench-to-clinic pipeline
In silico: network pharmacology for Nrf2, NF-κB, AKT, WNT, MMPs, EGFR-Src, miRNAs, and apoptosis nodes. HYPERLINK \l "fn299" \h [299] HYPERLINK \l "fn303" \h [303] HYPERLINK \l "fn297" \h [297] HYPERLINK \l "fn298" \h [298] HYPERLINK \l "fn295" \h [295]
In vitro: CAL-27, SCC-25, SAS, OECM-1 and normal oral epithelial controls; measure ROS, apoptosis, Ki-67, caspases, MMP-2/9, p-AKT, NF-κB and miRNA signatures. HYPERLINK \l "fn297" \h [297] HYPERLINK \l "fn298" \h [298] HYPERLINK \l "fn299" \h [299] HYPERLINK \l "fn300" \h [300]
Ex vivo / organotypic mucosa: evaluate mucoadhesion, permeation, irritation, and local retention.
Pilot clinical: high-risk oral-premalignant lesions or post-treatment field cancerization, with symptom and biomarker endpoints. HYPERLINK \l "fn306" \h [306] HYPERLINK \l "fn295" \h [295] HYPERLINK \l "fn300" \h [300]
Product dossier summary
This is a multi-target oral mucosal nutraceutical-adjunct based on quercetin-rutin-apigenin with chlorophyllin and low-dose ABA, optionally paired with piperine and adaptogens, designed to address oxidative damage, proliferation, inflammation and signaling dysregulation in oral cancer. Its differentiators are local oral delivery, biomarker-guided personalization, and dual-use SKUs for prevention and adjunct therapy. HYPERLINK \l "fn316" \h [316] HYPERLINK \l "fn312" \h [312] HYPERLINK \l "fn313" \h [313] HYPERLINK \l "fn295" \h [295] HYPERLINK \l "fn300" \h [300]Potential IP claims can focus on:
the ratio window of flavonoids to chlorophyllin/ABA,
a mucoadhesive nano-enabled oral film or gel,
biomarker-driven patient stratification, and
co-administration timing with standard therapy to reduce toxicity and improve efficacy. HYPERLINK \l "fn319" \h [319] HYPERLINK \l "fn296" \h [296] HYPERLINK \l "fn313" \h [313] HYPERLINK \l "fn316" \h [316] HYPERLINK \l "fn300" \h [300]
Regulatory note
For FDA-facing positioning, the safer categories are dietary supplement, oral care adjunct, or medical food depending on claims and route; avoid treatment claims unless pursuing a botanical drug pathway. HYPERLINK \l "fn320" \h [320] HYPERLINK \l "fn321" \h [321] HYPERLINK \l "fn322" \h [322]
If you want, I can convert this into a patient-stratified dosing algorithm with biomarker thresholds and a concise product claim matrix.
⁂

HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC9505045/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC9505045/     
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/35674735/" \h https://pubmed.ncbi.nlm.nih.gov/35674735/      
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/       
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41235439/" \h https://pubmed.ncbi.nlm.nih.gov/41235439/       
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/291350/preprint_pdf/1d3059cd147138a5fb2b7cd8824a63c7.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/291350/preprint_pdf/1d3059cd147138a5fb2b7cd8824a63c7.pdf     
 HYPERLINK "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full" \h https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full       
 HYPERLINK "https://www.foodandnutritionjournal.org/volume14number1/phyto-flavonoids-in-cancer-therapy-emerging-insights-and-future-perspectives/" \h https://www.foodandnutritionjournal.org/volume14number1/phyto-flavonoids-in-cancer-therapy-emerging-insights-and-future-perspectives/                   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/     
 HYPERLINK "https://nanobioletters.com/wp-content/lianbs/2025/11/LIANBS144.232.pdf" \h https://nanobioletters.com/wp-content/lianbs/2025/11/LIANBS144.232.pdf    
paste.txt     
 HYPERLINK "https://www.jcpjournal.org/journal/view.html?doi=10.15430%2FJCP.2016.21.4.216" \h https://www.jcpjournal.org/journal/view.html?doi=10.15430%2FJCP.2016.21.4.216 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/39318018/" \h https://pubmed.ncbi.nlm.nih.gov/39318018/      
 HYPERLINK "https://digitalscholar.lsuhsc.edu/cgi/viewcontent.cgi?article=1453&context=sogs_facpubs" \h https://digitalscholar.lsuhsc.edu/cgi/viewcontent.cgi?article=1453&context=sogs_facpubs  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12734382/table/jcm-14-08894-t001/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12734382/table/jcm-14-08894-t001/    
 HYPERLINK "https://www.experimentalbiomedicalresearch.com/index.php/ebr/article/download/490/251/5114" \h https://www.experimentalbiomedicalresearch.com/index.php/ebr/article/download/490/251/5114 
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/291533/preprint_pdf/6f03c48d4cbb00b83e4728151f66ca06.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/291533/preprint_pdf/6f03c48d4cbb00b83e4728151f66ca06.pdf 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2020095236A1?lens_id=025-451-786-758-454" \h https://www.perplexity.ai/rest/file-repository/patents/WO2020095236A1?lens_id=025-451-786-758-454      
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20200138843A1?lens_id=138-361-290-418-50X" \h https://www.perplexity.ai/rest/file-repository/patents/US20200138843A1?lens_id=138-361-290-418-50X      
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824" \h https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824         
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US6514527B1?lens_id=142-636-833-006-881" \h https://www.perplexity.ai/rest/file-repository/patents/US6514527B1?lens_id=142-636-833-006-881        
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/EP1319405A1?lens_id=142-658-320-715-946" \h https://www.perplexity.ai/rest/file-repository/patents/EP1319405A1?lens_id=142-658-320-715-946        
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936" \h https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936       
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680" \h https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680       
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2023150694A1?lens_id=136-967-825-298-887" \h https://www.perplexity.ai/rest/file-repository/patents/WO2023150694A1?lens_id=136-967-825-298-887      
 HYPERLINK "https://onlinelibrary.wiley.com/doi/10.1002/med.21969" \h https://onlinelibrary.wiley.com/doi/10.1002/med.21969                     
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20030022845A1?lens_id=071-818-655-431-503" \h https://www.perplexity.ai/rest/file-repository/patents/US20030022845A1?lens_id=071-818-655-431-503     
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2000025795A1?lens_id=099-601-614-140-776" \h https://www.perplexity.ai/rest/file-repository/patents/WO2000025795A1?lens_id=099-601-614-140-776     
 HYPERLINK "https://www.clinicaltrials.gov/study/NCT03476330" \h https://www.clinicaltrials.gov/study/NCT03476330   
 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials/intervention/quercetin?pn=1" \h https://www.cancer.gov/research/participate/clinical-trials/intervention/quercetin?pn=1 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/31257059/" \h https://pubmed.ncbi.nlm.nih.gov/31257059/  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8771640/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8771640/  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41235439/" \h https://pubmed.ncbi.nlm.nih.gov/41235439/  
 HYPERLINK "https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/" \h https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/23969487/" \h https://pubmed.ncbi.nlm.nih.gov/23969487/   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC9505045/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC9505045/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/ 
 HYPERLINK "https://ompj.org/files/article%203%20Anitha%20Roy%20%20164-168-bf9b2e79b17413d247ac07d672960da190270811.pdf" \h https://ompj.org/files/article 3 Anitha Roy 164-168-bf9b2e79b17413d247ac07d672960da190270811.pdf  
 HYPERLINK "https://revistas.ucr.ac.cr/index.php/rOdontos/article/view/5691" \h https://revistas.ucr.ac.cr/index.php/rOdontos/article/view/5691   
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/291350/preprint_pdf/1d3059cd147138a5fb2b7cd8824a63c7.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/291350/preprint_pdf/1d3059cd147138a5fb2b7cd8824a63c7.pdf  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12734382/table/jcm-14-08894-t001/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12734382/table/jcm-14-08894-t001/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/35674735/" \h https://pubmed.ncbi.nlm.nih.gov/35674735/ 
 HYPERLINK "https://nanobioletters.com/wp-content/lianbs/2025/11/LIANBS144.232.pdf" \h https://nanobioletters.com/wp-content/lianbs/2025/11/LIANBS144.232.pdf  
 HYPERLINK "https://cdn.clinicaltrials.gov/large-docs/30/NCT03476330/ICF_001.pdf" \h https://cdn.clinicaltrials.gov/large-docs/30/NCT03476330/ICF_001.pdf 
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/291533/preprint_pdf/6f03c48d4cbb00b83e4728151f66ca06.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/291533/preprint_pdf/6f03c48d4cbb00b83e4728151f66ca06.pdf 
 HYPERLINK "https://clinicaltrials.gov/study/NCT05456022" \h https://clinicaltrials.gov/study/NCT05456022 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/   
 HYPERLINK "https://www.sciencedirect.com/science/article/abs/pii/S0014299921005537" \h https://www.sciencedirect.com/science/article/abs/pii/S0014299921005537      
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34332920/" \h https://pubmed.ncbi.nlm.nih.gov/34332920/            
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41235439/" \h https://pubmed.ncbi.nlm.nih.gov/41235439/      
 HYPERLINK "https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/" \h https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/   
 HYPERLINK "https://onlinelibrary.wiley.com/doi/10.1002/med.21969" \h https://onlinelibrary.wiley.com/doi/10.1002/med.21969                   
 HYPERLINK "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141288/table/T2/" \h https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141288/table/T2/     
 HYPERLINK "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1810344/full" \h https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1810344/full     
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/     
 HYPERLINK "https://journal.waocp.org/article_91313_aa625453ed77bdf0e59ae845338b1b08.pdf" \h https://journal.waocp.org/article_91313_aa625453ed77bdf0e59ae845338b1b08.pdf 
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S2251729412000328" \h https://www.sciencedirect.com/science/article/pii/S2251729412000328   
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/291350/preprint_pdf/1d3059cd147138a5fb2b7cd8824a63c7.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/291350/preprint_pdf/1d3059cd147138a5fb2b7cd8824a63c7.pdf     
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC3992969/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC3992969/       
 HYPERLINK "https://onlinelibrary.wiley.com/doi/full/10.1155/2024/5594462" \h https://onlinelibrary.wiley.com/doi/full/10.1155/2024/5594462  
paste.txt 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US6514527B1?lens_id=142-636-833-006-881" \h https://www.perplexity.ai/rest/file-repository/patents/US6514527B1?lens_id=142-636-833-006-881 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/EP1319405A1?lens_id=142-658-320-715-946" \h https://www.perplexity.ai/rest/file-repository/patents/EP1319405A1?lens_id=142-658-320-715-946 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20030022845A1?lens_id=071-818-655-431-503" \h https://www.perplexity.ai/rest/file-repository/patents/US20030022845A1?lens_id=071-818-655-431-503 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2000025795A1?lens_id=099-601-614-140-776" \h https://www.perplexity.ai/rest/file-repository/patents/WO2000025795A1?lens_id=099-601-614-140-776 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/23969487/" \h https://pubmed.ncbi.nlm.nih.gov/23969487/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/35674735/" \h https://pubmed.ncbi.nlm.nih.gov/35674735/   
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/269814/preprint_pdf/74ec703898cac3d49439e7130b5a7b3a.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/269814/preprint_pdf/74ec703898cac3d49439e7130b5a7b3a.pdf 
 HYPERLINK "https://ijpsdronline.com/index.php/journal/article/download/4377/895" \h https://ijpsdronline.com/index.php/journal/article/download/4377/895 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41235439/" \h https://pubmed.ncbi.nlm.nih.gov/41235439/      
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41294558/" \h https://pubmed.ncbi.nlm.nih.gov/41294558/    
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/39686635/" \h https://pubmed.ncbi.nlm.nih.gov/39686635/         
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/36007853/" \h https://pubmed.ncbi.nlm.nih.gov/36007853/        
 HYPERLINK "https://www.clinicaltrials.gov/study/NCT03476330" \h https://www.clinicaltrials.gov/study/NCT03476330  
 HYPERLINK "https://www.cancer.gov/research/participate/clinical-trials/intervention/quercetin?pn=1" \h https://www.cancer.gov/research/participate/clinical-trials/intervention/quercetin?pn=1 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824" \h https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824       
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936" \h https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936       
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680" \h https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680       
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12734382/table/jcm-14-08894-t001/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12734382/table/jcm-14-08894-t001/   
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/291350/preprint_pdf/1d3059cd147138a5fb2b7cd8824a63c7.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/291350/preprint_pdf/1d3059cd147138a5fb2b7cd8824a63c7.pdf   
 HYPERLINK "https://onlinelibrary.wiley.com/doi/10.1002/med.21969" \h https://onlinelibrary.wiley.com/doi/10.1002/med.21969   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12764730/table/Tab3/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12764730/table/Tab3/    
 HYPERLINK "https://www.springermedicine.com/oral-cancer/oral-cavity-carcinoma/therapeutic-effects-of-quercetin-in-oral-cancer-therapy-a-system/50674714" \h https://www.springermedicine.com/oral-cancer/oral-cavity-carcinoma/therapeutic-effects-of-quercetin-in-oral-cancer-therapy-a-system/50674714 
 HYPERLINK "https://www.sciencedirect.com/science/article/abs/pii/S0014299921005537" \h https://www.sciencedirect.com/science/article/abs/pii/S0014299921005537 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34332920/" \h https://pubmed.ncbi.nlm.nih.gov/34332920/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC9171451/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC9171451/ 
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/291533/preprint_pdf/6f03c48d4cbb00b83e4728151f66ca06.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/291533/preprint_pdf/6f03c48d4cbb00b83e4728151f66ca06.pdf 
 HYPERLINK "https://pubs.rsc.org/en/content/articlepdf/2026/na/d5na00546a" \h https://pubs.rsc.org/en/content/articlepdf/2026/na/d5na00546a 
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S0753332220305655" \h https://www.sciencedirect.com/science/article/pii/S0753332220305655 
 HYPERLINK "https://onlinelibrary.wiley.com/doi/full/10.1155/2024/5594462" \h https://onlinelibrary.wiley.com/doi/full/10.1155/2024/5594462 
 HYPERLINK "http://www.idr.iitkgp.ac.in/xmlui/bitstream/handle/123456789/6092/NB15349_Abstract.pdf?sequence=3" \h http://www.idr.iitkgp.ac.in/xmlui/bitstream/handle/123456789/6092/NB15349_Abstract.pdf?sequence=3 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085606/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8085606/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC9609346/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC9609346/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12985067/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12985067/   
 HYPERLINK "https://www.sciencedirect.com/science/article/abs/pii/S1549963413007752" \h https://www.sciencedirect.com/science/article/abs/pii/S1549963413007752   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41235439/" \h https://pubmed.ncbi.nlm.nih.gov/41235439/     
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/23792276/" \h https://pubmed.ncbi.nlm.nih.gov/23792276/      
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/27033463/" \h https://pubmed.ncbi.nlm.nih.gov/27033463/      
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/40025673/" \h https://pubmed.ncbi.nlm.nih.gov/40025673/        
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34332920/" \h https://pubmed.ncbi.nlm.nih.gov/34332920/    
 HYPERLINK "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1810344/full" \h https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1810344/full  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/  
 HYPERLINK "https://ctri.nic.in/Clinicaltrials/showallp.php?mid1=19801&EncHid=&userName=CTRI%2F2018%2F03%2F012459" \h https://ctri.nic.in/Clinicaltrials/showallp.php?mid1=19801&EncHid=&userName=CTRI%2F2018%2F03%2F012459    
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41294558/" \h https://pubmed.ncbi.nlm.nih.gov/41294558/   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/39686635/" \h https://pubmed.ncbi.nlm.nih.gov/39686635/     
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/36007853/" \h https://pubmed.ncbi.nlm.nih.gov/36007853/     
 HYPERLINK "https://trial.medpath.com/clinical-trial/776deaca49bdcc2e/ctri/2023/07/055047-chlorophyllin-radioprotective-head-neck-cancer-radiation" \h https://trial.medpath.com/clinical-trial/776deaca49bdcc2e/ctri/2023/07/055047-chlorophyllin-radioprotective-head-neck-cancer-radiation   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11851190/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11851190/   
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US6514527B1?lens_id=142-636-833-006-881" \h https://www.perplexity.ai/rest/file-repository/patents/US6514527B1?lens_id=142-636-833-006-881  
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/EP1319405A1?lens_id=142-658-320-715-946" \h https://www.perplexity.ai/rest/file-repository/patents/EP1319405A1?lens_id=142-658-320-715-946  
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20030022845A1?lens_id=071-818-655-431-503" \h https://www.perplexity.ai/rest/file-repository/patents/US20030022845A1?lens_id=071-818-655-431-503  
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2000025795A1?lens_id=099-601-614-140-776" \h https://www.perplexity.ai/rest/file-repository/patents/WO2000025795A1?lens_id=099-601-614-140-776  
 HYPERLINK "https://onlinelibrary.wiley.com/doi/10.1111/jfbc.14060" \h https://onlinelibrary.wiley.com/doi/10.1111/jfbc.14060   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC4580003/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC4580003/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11750326/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11750326/ 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2020095236A1?lens_id=025-451-786-758-454" \h https://www.perplexity.ai/rest/file-repository/patents/WO2020095236A1?lens_id=025-451-786-758-454 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20200138843A1?lens_id=138-361-290-418-50X" \h https://www.perplexity.ai/rest/file-repository/patents/US20200138843A1?lens_id=138-361-290-418-50X 
 HYPERLINK "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141288/table/T2/" \h https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3141288/table/T2/ 
 HYPERLINK "https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/" \h https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/31257059/" \h https://pubmed.ncbi.nlm.nih.gov/31257059/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8771640/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8771640/ 
 HYPERLINK "https://revistas.ucr.ac.cr/index.php/rOdontos/article/view/5691" \h https://revistas.ucr.ac.cr/index.php/rOdontos/article/view/5691 
 HYPERLINK "https://trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12618001718235" \h https://trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12618001718235 
 HYPERLINK "https://www.who.int/tools/clinical-trials-registry-platform/the-ictrp-search-portal" \h https://www.who.int/tools/clinical-trials-registry-platform/the-ictrp-search-portal 
 HYPERLINK "https://www.bium.ch/en/documents/clinical-trials-register/ictrp-who-international-clinical-trials-registry-platform/" \h https://www.bium.ch/en/documents/clinical-trials-register/ictrp-who-international-clinical-trials-registry-platform/ 
 HYPERLINK "https://sites.google.com/a/york.ac.uk/yhectrialsregisters/home/clinicaltrials/ictrp" \h https://sites.google.com/a/york.ac.uk/yhectrialsregisters/home/clinicaltrials/ictrp 
 HYPERLINK "https://ctri.nic.in/Clinicaltrials/showallp.php?mid1=69346&EncHid=&userName=CTRI%2F2022%2F06%2F043203" \h https://ctri.nic.in/Clinicaltrials/showallp.php?mid1=69346&EncHid=&userName=CTRI%2F2022%2F06%2F043203  
 HYPERLINK "https://doaj.org/article/b37abb30820d45e18119a3a53f69ed8b" \h https://doaj.org/article/b37abb30820d45e18119a3a53f69ed8b 
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/291350/preprint_pdf/1d3059cd147138a5fb2b7cd8824a63c7.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/291350/preprint_pdf/1d3059cd147138a5fb2b7cd8824a63c7.pdf 
 HYPERLINK "https://onlinelibrary.wiley.com/doi/10.1002/med.21969" \h https://onlinelibrary.wiley.com/doi/10.1002/med.21969   
 HYPERLINK "https://www.clinicaltrials.gov/study/NCT03476330" \h https://www.clinicaltrials.gov/study/NCT03476330 
 HYPERLINK "https://www.sciencedirect.com/science/article/abs/pii/S0014299921005537" \h https://www.sciencedirect.com/science/article/abs/pii/S0014299921005537 
 HYPERLINK "https://patents.google.com/patent/WO2005082407A1/en" \h https://patents.google.com/patent/WO2005082407A1/en 
 HYPERLINK "https://www.mskcc.org/cancer-care/integrative-medicine/herbs/quercetin" \h https://www.mskcc.org/cancer-care/integrative-medicine/herbs/quercetin 
 HYPERLINK "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.860209/full" \h https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.860209/full 
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/291533/preprint_pdf/6f03c48d4cbb00b83e4728151f66ca06.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/291533/preprint_pdf/6f03c48d4cbb00b83e4728151f66ca06.pdf 
 HYPERLINK "https://ctri.nic.in/Clinicaltrials/showallp.php?mid1=84344&EncHid=&userName=CTRI%2F2023%2F05%2F052728" \h https://ctri.nic.in/Clinicaltrials/showallp.php?mid1=84344&EncHid=&userName=CTRI%2F2023%2F05%2F052728 
 HYPERLINK "https://www.who.int/tools/clinical-trials-registry-platform/the-ictrp-search-portal/search-tips" \h https://www.who.int/tools/clinical-trials-registry-platform/the-ictrp-search-portal/search-tips 
 HYPERLINK "https://clinicaltrials.gov/study/NCT05456022" \h https://clinicaltrials.gov/study/NCT05456022 
 HYPERLINK "https://www.clinicaltrials.gov/study/NCT06016452" \h https://www.clinicaltrials.gov/study/NCT06016452 
 HYPERLINK "https://ctri.nic.in/Clinicaltrials/showallp.php?mid1=44886" \h https://ctri.nic.in/Clinicaltrials/showallp.php?mid1=44886 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/35092896/" \h https://pubmed.ncbi.nlm.nih.gov/35092896/        
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34587428/" \h https://pubmed.ncbi.nlm.nih.gov/34587428/      
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41235439/" \h https://pubmed.ncbi.nlm.nih.gov/41235439/    
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/    
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12633408/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12633408/        
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12985067/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12985067/    
 HYPERLINK "https://www.sciencedirect.com/science/article/abs/pii/S0944711321004499" \h https://www.sciencedirect.com/science/article/abs/pii/S0944711321004499    
 HYPERLINK "https://ouci.dntb.gov.ua/en/works/7neQrmP9/" \h https://ouci.dntb.gov.ua/en/works/7neQrmP9/ 
 HYPERLINK "https://onlinelibrary.wiley.com/doi/10.1111/jfbc.14060" \h https://onlinelibrary.wiley.com/doi/10.1111/jfbc.14060   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/39686635/" \h https://pubmed.ncbi.nlm.nih.gov/39686635/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/36007853/" \h https://pubmed.ncbi.nlm.nih.gov/36007853/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41294558/" \h https://pubmed.ncbi.nlm.nih.gov/41294558/  
 HYPERLINK "https://trial.medpath.com/clinical-trial/776deaca49bdcc2e/ctri/2023/07/055047-chlorophyllin-radioprotective-head-neck-cancer-radiation" \h https://trial.medpath.com/clinical-trial/776deaca49bdcc2e/ctri/2023/07/055047-chlorophyllin-radioprotective-head-neck-cancer-radiation  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11851190/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11851190/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/40025673/" \h https://pubmed.ncbi.nlm.nih.gov/40025673/  
 HYPERLINK "https://onlinelibrary.wiley.com/doi/10.1002/med.21969" \h https://onlinelibrary.wiley.com/doi/10.1002/med.21969  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34332920/" \h https://pubmed.ncbi.nlm.nih.gov/34332920/   
 HYPERLINK "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1810344/full" \h https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1810344/full 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/ 
 HYPERLINK "https://www.sciencedirect.com/science/article/abs/pii/S1549963413007752" \h https://www.sciencedirect.com/science/article/abs/pii/S1549963413007752 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/23792276/" \h https://pubmed.ncbi.nlm.nih.gov/23792276/ 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824" \h https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824   
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936" \h https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936   
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680" \h https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/36746272/" \h https://pubmed.ncbi.nlm.nih.gov/36746272/    
 HYPERLINK "https://www.semanticscholar.org/paper/FORMULATION-AND-EVALUATION-OF-QUERCETIN-FOR-OF-VIA-Savale/4a3550419139672f7313704fbd67d3f3713f63b2" \h https://www.semanticscholar.org/paper/FORMULATION-AND-EVALUATION-OF-QUERCETIN-FOR-OF-VIA-Savale/4a3550419139672f7313704fbd67d3f3713f63b2  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/ 
 HYPERLINK "https://doaj.org/article/b37abb30820d45e18119a3a53f69ed8b" \h https://doaj.org/article/b37abb30820d45e18119a3a53f69ed8b 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC4580003/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC4580003/  
 HYPERLINK "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.860209/full" \h https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.860209/full 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11750326/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11750326/  
 HYPERLINK "https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/" \h https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/31257059/" \h https://pubmed.ncbi.nlm.nih.gov/31257059/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8771640/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8771640/ 
 HYPERLINK "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1794285/full" \h https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1794285/full 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/39002062/" \h https://pubmed.ncbi.nlm.nih.gov/39002062/ 
 HYPERLINK "https://www.rjpn.org/ijnti/papers/IJNTI2603099.pdf" \h https://www.rjpn.org/ijnti/papers/IJNTI2603099.pdf 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41368332/" \h https://pubmed.ncbi.nlm.nih.gov/41368332/ 
 HYPERLINK "https://pubs.rsc.org/en/content/articlepdf/2025/na/d5na00546a" \h https://pubs.rsc.org/en/content/articlepdf/2025/na/d5na00546a 
 HYPERLINK "https://onlinelibrary.wiley.com/doi/full/10.1155/2024/5594462" \h https://onlinelibrary.wiley.com/doi/full/10.1155/2024/5594462 
 HYPERLINK "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full" \h https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full     
 HYPERLINK "https://www.foodandnutritionjournal.org/volume14number1/phyto-flavonoids-in-cancer-therapy-emerging-insights-and-future-perspectives/" \h https://www.foodandnutritionjournal.org/volume14number1/phyto-flavonoids-in-cancer-therapy-emerging-insights-and-future-perspectives/    
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/    
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34829751/" \h https://pubmed.ncbi.nlm.nih.gov/34829751/      
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S2405844025010631" \h https://www.sciencedirect.com/science/article/pii/S2405844025010631    
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41235439/" \h https://pubmed.ncbi.nlm.nih.gov/41235439/    
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC2874462/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC2874462/  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12252104/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12252104/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34587428/" \h https://pubmed.ncbi.nlm.nih.gov/34587428/      
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/36746272/" \h https://pubmed.ncbi.nlm.nih.gov/36746272/   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12633408/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12633408/      
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824" \h https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824  
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936" \h https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936  
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680" \h https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC3992969/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC3992969/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/35092896/" \h https://pubmed.ncbi.nlm.nih.gov/35092896/    
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34332920/" \h https://pubmed.ncbi.nlm.nih.gov/34332920/  
 HYPERLINK "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1810344/full" \h https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1810344/full 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/23792276/" \h https://pubmed.ncbi.nlm.nih.gov/23792276/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41294558/" \h https://pubmed.ncbi.nlm.nih.gov/41294558/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/39686635/" \h https://pubmed.ncbi.nlm.nih.gov/39686635/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/36007853/" \h https://pubmed.ncbi.nlm.nih.gov/36007853/ 
 HYPERLINK "https://pubs.rsc.org/en/content/articlepdf/2025/na/d5na00546a" \h https://pubs.rsc.org/en/content/articlepdf/2025/na/d5na00546a 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/42123822/" \h https://pubmed.ncbi.nlm.nih.gov/42123822/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12661057/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12661057/ 
 HYPERLINK "https://www.semanticscholar.org/paper/FORMULATION-AND-EVALUATION-OF-QUERCETIN-FOR-OF-VIA-Savale/4a3550419139672f7313704fbd67d3f3713f63b2" \h https://www.semanticscholar.org/paper/FORMULATION-AND-EVALUATION-OF-QUERCETIN-FOR-OF-VIA-Savale/4a3550419139672f7313704fbd67d3f3713f63b2 
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S1726490112003334" \h https://www.sciencedirect.com/science/article/pii/S1726490112003334 
 HYPERLINK "https://www.springermedicine.com/oral-cancer/oral-cavity-carcinoma/therapeutic-effects-of-quercetin-in-oral-cancer-therapy-a-system/50674714" \h https://www.springermedicine.com/oral-cancer/oral-cavity-carcinoma/therapeutic-effects-of-quercetin-in-oral-cancer-therapy-a-system/50674714 
 HYPERLINK "https://journal.waocp.org/article_89560_f1b7b2ebd250adb4a4d54c7946a57672.pdf,https:/www.ncbi.nlm.nih.gov/pubmed/33906311,https:/pubmed.ncbi.nlm.nih.gov/33906311/,https:/www.ncbi.nlm.nih.gov/pmc/articles/PMC8325144,http:/journal.waocp.org/article_91727_96445c2f976993ced9fa000b3c4d5416.pdf" \h https://journal.waocp.org/article_89560_f1b7b2ebd250adb4a4d54c7946a57672.pdf,https:/www.ncbi.nlm.nih.gov/pubmed/33906311,https:/pubmed.ncbi.nlm.nih.gov/33906311/,https:/www.ncbi.nlm.nih.gov/pmc/articles/PMC8325144,http:/journal.waocp.org/article_91727_96445c2f976993ced9fa000b3c4d5416.pdf 
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/291533/preprint_pdf/6f03c48d4cbb00b83e4728151f66ca06.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/291533/preprint_pdf/6f03c48d4cbb00b83e4728151f66ca06.pdf 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/39318018/" \h https://pubmed.ncbi.nlm.nih.gov/39318018/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/      
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41235439/" \h https://pubmed.ncbi.nlm.nih.gov/41235439/     
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/32521182/" \h https://pubmed.ncbi.nlm.nih.gov/32521182/    
 HYPERLINK "https://www.airitilibrary.com/Article/Detail/U0003-2207201619280800" \h https://www.airitilibrary.com/Article/Detail/U0003-2207201619280800  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11422005/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11422005/    
 HYPERLINK "https://www.springermedizin.de/quercetin-triggers-cell-apoptosis-associated-ros-mediated-cell-d/50577878" \h https://www.springermedizin.de/quercetin-triggers-cell-apoptosis-associated-ros-mediated-cell-d/50577878 
 HYPERLINK "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full" \h https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full    
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC2874462/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC2874462/   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/35092896/" \h https://pubmed.ncbi.nlm.nih.gov/35092896/      
 HYPERLINK "https://www.sciencedirect.com/science/article/abs/pii/S0944711321004499" \h https://www.sciencedirect.com/science/article/abs/pii/S0944711321004499  
 HYPERLINK "https://ouci.dntb.gov.ua/en/works/7neQrmP9/" \h https://ouci.dntb.gov.ua/en/works/7neQrmP9/ 
 HYPERLINK "https://trial.medpath.com/clinical-trial/776deaca49bdcc2e/ctri/2023/07/055047-chlorophyllin-radioprotective-head-neck-cancer-radiation" \h https://trial.medpath.com/clinical-trial/776deaca49bdcc2e/ctri/2023/07/055047-chlorophyllin-radioprotective-head-neck-cancer-radiation  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11851190/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11851190/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/40025673/" \h https://pubmed.ncbi.nlm.nih.gov/40025673/  
 HYPERLINK "https://onlinelibrary.wiley.com/doi/10.1002/med.21969" \h https://onlinelibrary.wiley.com/doi/10.1002/med.21969 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/ 
 HYPERLINK "https://www.foodandnutritionjournal.org/volume14number1/phyto-flavonoids-in-cancer-therapy-emerging-insights-and-future-perspectives/" \h https://www.foodandnutritionjournal.org/volume14number1/phyto-flavonoids-in-cancer-therapy-emerging-insights-and-future-perspectives/ 
 HYPERLINK "https://onlinelibrary.wiley.com/doi/10.1111/jfbc.14060" \h https://onlinelibrary.wiley.com/doi/10.1111/jfbc.14060 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34829751/" \h https://pubmed.ncbi.nlm.nih.gov/34829751/  
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S2405844025010631" \h https://www.sciencedirect.com/science/article/pii/S2405844025010631  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC6750792/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC6750792/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12985067/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12985067/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34587428/" \h https://pubmed.ncbi.nlm.nih.gov/34587428/   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/36746272/" \h https://pubmed.ncbi.nlm.nih.gov/36746272/  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12633408/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12633408/       
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824" \h https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824  
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936" \h https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936  
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680" \h https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC3992969/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC3992969/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34332920/" \h https://pubmed.ncbi.nlm.nih.gov/34332920/  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/ 
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S1726490112003334" \h https://www.sciencedirect.com/science/article/pii/S1726490112003334 
 HYPERLINK "https://onlinelibrary.wiley.com/doi/full/10.1111/ajco.70046" \h https://onlinelibrary.wiley.com/doi/full/10.1111/ajco.70046 
 HYPERLINK "https://www.springermedicine.com/oral-cancer/oral-cavity-carcinoma/therapeutic-effects-of-quercetin-in-oral-cancer-therapy-a-system/50674714" \h https://www.springermedicine.com/oral-cancer/oral-cavity-carcinoma/therapeutic-effects-of-quercetin-in-oral-cancer-therapy-a-system/50674714 
 HYPERLINK "https://academy.miloa.eu/wp-content/uploads/2020/06/Anticancer-potential-of-quercetin_-A-comprehensive-review.pdf" \h https://academy.miloa.eu/wp-content/uploads/2020/06/Anticancer-potential-of-quercetin_-A-comprehensive-review.pdf 
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S0753332219352266" \h https://www.sciencedirect.com/science/article/pii/S0753332219352266 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11750326/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11750326/ 
 HYPERLINK "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1547992/full" \h https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1547992/full 
 HYPERLINK "https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/" \h https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/22210229/" \h https://pubmed.ncbi.nlm.nih.gov/22210229/      
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34332920/" \h https://pubmed.ncbi.nlm.nih.gov/34332920/          
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41235439/" \h https://pubmed.ncbi.nlm.nih.gov/41235439/       
 HYPERLINK "https://www.sciencedirect.com/science/article/abs/pii/S1773224724000029" \h https://www.sciencedirect.com/science/article/abs/pii/S1773224724000029 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/27033463/" \h https://pubmed.ncbi.nlm.nih.gov/27033463/   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC5629766/  
 HYPERLINK "https://www.foodandnutritionjournal.org/volume14number1/phyto-flavonoids-in-cancer-therapy-emerging-insights-and-future-perspectives/" \h https://www.foodandnutritionjournal.org/volume14number1/phyto-flavonoids-in-cancer-therapy-emerging-insights-and-future-perspectives/    
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34829751/" \h https://pubmed.ncbi.nlm.nih.gov/34829751/ 
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S2405844025010631" \h https://www.sciencedirect.com/science/article/pii/S2405844025010631 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC3992969/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC3992969/    
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S2251729412000328" \h https://www.sciencedirect.com/science/article/pii/S2251729412000328 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12252104/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12252104/  
paste.txt  
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824" \h https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824       
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936" \h https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936       
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680" \h https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680       
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12985067/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12985067/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11422005/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11422005/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12633408/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12633408/   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/35092896/" \h https://pubmed.ncbi.nlm.nih.gov/35092896/    
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41294558/" \h https://pubmed.ncbi.nlm.nih.gov/41294558/  
 HYPERLINK "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full" \h https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC2874462/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC2874462/ 
 HYPERLINK "https://onlinelibrary.wiley.com/doi/10.1002/med.21969" \h https://onlinelibrary.wiley.com/doi/10.1002/med.21969 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12239925/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12239925/  
 HYPERLINK "https://www.sciencedirect.com/science/article/abs/pii/S0944711321004499" \h https://www.sciencedirect.com/science/article/abs/pii/S0944711321004499 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34587428/" \h https://pubmed.ncbi.nlm.nih.gov/34587428/ 
 HYPERLINK "https://www.ijlpr.com/index.php/journal/article/view/1389" \h https://www.ijlpr.com/index.php/journal/article/view/1389 
 HYPERLINK "https://d197for5662m48.cloudfront.net/documents/publicationstatus/269814/preprint_pdf/74ec703898cac3d49439e7130b5a7b3a.pdf" \h https://d197for5662m48.cloudfront.net/documents/publicationstatus/269814/preprint_pdf/74ec703898cac3d49439e7130b5a7b3a.pdf 
 HYPERLINK "https://onlinelibrary.wiley.com/doi/full/10.1155/2024/5594462" \h https://onlinelibrary.wiley.com/doi/full/10.1155/2024/5594462 
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S1726490112003334" \h https://www.sciencedirect.com/science/article/pii/S1726490112003334 
 HYPERLINK "https://www.sciencedirect.com/science/article/abs/pii/S0014299921005537" \h https://www.sciencedirect.com/science/article/abs/pii/S0014299921005537 
 HYPERLINK "https://www.tandfonline.com/doi/full/10.1080/10942912.2023.2252619" \h https://www.tandfonline.com/doi/full/10.1080/10942912.2023.2252619 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11854426/         
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11422005/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11422005/      
 HYPERLINK "https://www.sciencedirect.com/science/article/abs/pii/S0014299919300147" \h https://www.sciencedirect.com/science/article/abs/pii/S0014299919300147     
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/30639311/" \h https://pubmed.ncbi.nlm.nih.gov/30639311/    
 HYPERLINK "https://journals.sagepub.com/doi/10.1177/0960327121991912" \h https://journals.sagepub.com/doi/10.1177/0960327121991912     
 HYPERLINK "https://www.springermedizin.de/therapeutic-effects-of-quercetin-in-oral-cancer-therapy-a-system/50676792" \h https://www.springermedizin.de/therapeutic-effects-of-quercetin-in-oral-cancer-therapy-a-system/50676792       
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC4580003/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC4580003/ 
 HYPERLINK "https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full" \h https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.681477/full 
 HYPERLINK "https://www.foodandnutritionjournal.org/volume14number1/phyto-flavonoids-in-cancer-therapy-emerging-insights-and-future-perspectives/" \h https://www.foodandnutritionjournal.org/volume14number1/phyto-flavonoids-in-cancer-therapy-emerging-insights-and-future-perspectives/  
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC2874462/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC2874462/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/32521182/" \h https://pubmed.ncbi.nlm.nih.gov/32521182/  
 HYPERLINK "https://www.airitilibrary.com/Article/Detail/U0003-2207201619280800" \h https://www.airitilibrary.com/Article/Detail/U0003-2207201619280800   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/22210229/" \h https://pubmed.ncbi.nlm.nih.gov/22210229/   
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11851190/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11851190/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/40025673/" \h https://pubmed.ncbi.nlm.nih.gov/40025673/ 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34829751/" \h https://pubmed.ncbi.nlm.nih.gov/34829751/ 
 HYPERLINK "https://www.sciencedirect.com/science/article/pii/S2405844025010631" \h https://www.sciencedirect.com/science/article/pii/S2405844025010631 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/41235439/" \h https://pubmed.ncbi.nlm.nih.gov/41235439/   
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/34332920/" \h https://pubmed.ncbi.nlm.nih.gov/34332920/     
 HYPERLINK "https://onlinelibrary.wiley.com/doi/full/10.1111/ajco.70046" \h https://onlinelibrary.wiley.com/doi/full/10.1111/ajco.70046 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC8218931/  
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/35092896/" \h https://pubmed.ncbi.nlm.nih.gov/35092896/   
 HYPERLINK "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1810344/full" \h https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1810344/full 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC10670142/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12633408/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12633408/ 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824" \h https://www.perplexity.ai/rest/file-repository/patents/US20260090969A1?lens_id=130-620-715-899-824 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936" \h https://www.perplexity.ai/rest/file-repository/patents/US20210267870A1?lens_id=155-301-911-470-936 
 HYPERLINK "https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680" \h https://www.perplexity.ai/rest/file-repository/patents/WO2020012175A1?lens_id=053-440-286-453-680 
 HYPERLINK "https://www.jcancer.org/v10p4509.pdf" \h https://www.jcancer.org/v10p4509.pdf 
 HYPERLINK "https://pubmed.ncbi.nlm.nih.gov/10928101/" \h https://pubmed.ncbi.nlm.nih.gov/10928101/ 
 HYPERLINK "https://www.tandfonline.com/doi/abs/10.1207/s15327914nc5302_11" \h https://www.tandfonline.com/doi/abs/10.1207/s15327914nc5302_11 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC12683358/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC12683358/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC6004715/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC6004715/ 
 HYPERLINK "https://pmc.ncbi.nlm.nih.gov/articles/PMC11750326/" \h https://pmc.ncbi.nlm.nih.gov/articles/PMC11750326/ 
 HYPERLINK "https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/" \h https://jglobaloralhealth.org/therapeutic-potential-of-quercetin-in-oral-squamous-cell-carcinoma-mechanisms-epigenetic-modulation-and-anti-metastatic-effects/

Your AI API key

This is used only to analyse this document and is kept only in your current browser session on this server - it is never written to a file, never sent to the page's JavaScript, and never shown to anyone else. Get a key at openrouter.ai/keys.

You are responsible for your own AI provider usage costs. Requests made with your key are billed by your provider (e.g. OpenRouter) to your account, at their normal rates - this site does not charge you separately and cannot see or control your provider's pricing.